

```

Element Count :
Node 29: Limited
      N,N1


```

L1 STRUCTURE UPLOADED

$\Rightarrow d \mid 11$

L1 HAS NO ANSWERS

L1	STR
----	-----



G1 O, S, N, CH₂, CH, NH, C

G2 O, S, N

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:14:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED

97 ITERATIONS

46 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1350 TO 2530

PROJECTED ANSWERS: 514 TO 1326

L2 46 SEA SSS SAM L1

=> s ll sss full

FULL SEARCH INITIATED 10:14:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1813 TO ITERATE

100.0% PROCESSED

1813 ITERATIONS

715 ANSWERS

SEARCH TIME: 00.00.01

L3 715 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 10:14:42 ON 28 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Nov 2006 VOL 145 ISS 23

FILE LAST UPDATED: 27 Nov 2006 (20061127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 32 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM

ACCESSION NUMBER: 2006:1005390 CAPLUS

DOCUMENT NUMBER: 145:356814

TITLE:

Preparation of 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines and related compounds as

INVENTOR(S):

Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenke, Dirk; Santagostino, Marco; Paleari, Fabio; Doods, Henri; Arndt, Kirsten; Schaenzle, Gerhard

PATENT ASSIGNEE(S):

Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE:

PCT Int. Appl., 231pp.

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100009	A1	20060928	WO 2006-KP2515	20060318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NZ, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GU, HT, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NZ, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
WO 2005092880	A1	20051006	WO 2005-KP3094	20050323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NZ, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NZ, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
WO 2005103037	A2	20051103	WO 2005-KP4104	20050418
WO 2005103037	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NZ, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NZ, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)

910573-68-1P 910573-69-2P 910573-70-3P

910573-71-6P 910573-72-7P 910573-73-8P

910573-74-9P 910573-75-3P 910573-76-4P

910573-80-7P 910573-82-9P 910573-84-1P

910573-86-3P 910573-87-4P 910573-88-5P

910573-89-6P 910573-90-9P 910573-91-0P

910573-92-1P 910573-93-2P 910573-94-3P

910573-95-4P 910573-96-5P 910573-97-6P

910573-98-7P 910573-99-8P 910574-00-4P

910574-02-6P 910574-03-7P 910574-04-8P

910574-05-9P 910574-06-0P 910574-07-1P

910574-08-2P 910574-09-3P 910574-10-6P

910574-11-7P 910574-12-8P 910574-13-9P

910574-14-0P 910574-15-1P 910574-16-2P

910574-17-3P 910574-18-4P 910574-19-5P

910574-20-6P 910574-21-9P 910574-22-0P

910574-23-1P 910574-24-2P 910574-25-3P

910574-26-4P 910574-27-5P 910574-28-6P

910574-29-7P 910574-30-0P 910574-31-1P

910574-32-2P 910574-33-3P 910574-34-4P

910574-35-5P 910574-36-6P 910574-47-9P

910574-48-0P 910574-49-1P 910574-50-4P

910574-52-6P 910574-54-8P 910574-56-0P

910574-57-1P 910574-59-3P 910574-60-6P

910574-61-7P 910574-62-8P 910574-63-9P

910574-64-0P 910574-65-1P 910574-66-2P

910574-68-4P 910574-69-5P 910574-70-8P

910574-71-9P 910574-72-0P 910574-73-1P

910574-74-2P 910574-76-4P 910574-78-6P

910574-81-1P 910574-83-3P 910574-84-4P

910574-85-5P 910574-86-6P 910574-87-7P

910574-88-8P 910574-89-9P 910574-90-2P

910574-91-3P 910574-92-4P 910574-93-5P

910574-94-6P 910574-95-7P 910574-96-8P

910574-97-9P 910574-98-0P 910574-99-1P

910575-00-7P 910575-01-8P 910575-02-9P

910575-03-0P 910575-04-1P 910575-05-2P

910575-06-3P 910575-07-4P 910575-08-5P

910575-10-9P 910575-11-0P 910575-12-1P

910575-13-2P 910575-14-3P 910575-15-4P

910575-16-5P 910575-17-6P 910575-18-7P

910575-19-8P 910575-20-1P 910575-21-2P

910575-22-3P 910575-23-4P 910575-24-5P

910575-25-6P 910575-26-7P 910575-27-8P

910575-28-9P 910575-29-0P 910575-30-3P

910575-31-4P 910575-32-5P 910575-33-6P

910575-34-7P 910575-35-8P 910576-30-6P

910576-31-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(Prep. of 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines and related compds.

as CGRP receptor antagonists)

RN 866086-06-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-

2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)

AZ, BY, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GU, HT, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NZ, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

PRIORITY APPL. INFO.:

WO 2005-KP3094 A 20050323

WO 2005-KP4104 A 20050418

EP 2005-21283 A 20050929


DE 2004-102004015723A 20040329

DE 2004-102004019492A 20040422

OTHER SOURCE(S):

MARPAT 145:356814

GI




AB Title compds. I [X = CH₂, NH, O, etc.; R₁ = substituted 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines, etc.; R₂ = 5-methylquinoxalines, 8-methylimidazo[1,2-a]pyridines, etc.; R₃ = substituted piperidines, piperazines, etc.; R₄ = 4 to 7-membered cycloalkyl ring with proviso] and their pharmaceutically acceptable salts and formulations were prepared. For example, benzodiazepinylpiperidine II was prepared from 5-amino-m-cresol in 8-steps. In CGRP receptor inhibition assays, compds. I exhibited IC₅₀ values ≤ 10000 nM.

IT 866086-06-8P 868706-99-4P 910573-16-9P
910573-17-0P 910573-18-1P 910573-22-7P
910573-23-8P 910573-24-9P 910573-25-0P
910573-26-1P 910573-27-2P 910573-28-3P
910573-29-4P 910573-30-7P 910573-31-8P
910573-32-9P 910573-33-0P 910573-37-4P
910573-38-5P 910573-39-6P 910573-43-2P
910573-44-3P 910573-45-4P 910573-46-5P
910573-47-6P 910573-48-7P 910573-49-8P
910573-50-1P 910573-51-2P 910573-52-3P
910573-53-4P 910573-57-8P 910573-58-9P
910573-59-0P 910573-63-6P 910573-64-7P
910573-65-8P 910573-66-9P 910573-67-0P

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)


Absolute stereochemistry.



RN 868706-99-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-3,4-dimethyl-2-oxo-6-benzoxazolyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910573-16-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (1R)-1-[(4-hydroxyphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910573-17-0 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-((1R)-1-[(4-hydroxyphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-18-1 CAPLUS
 CN Piperazine, 1-[(2S)-4-[[4-((2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl)-2-[(4-hydroxyphenyl)methyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910573-24-9 CAPLUS
 CN Piperazine, 1-[(2S)-4-[[4-((2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl)-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-25-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-((1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910573-22-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-((1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-23-8 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-((1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-3-yl)-1-piperazinyl]ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910573-26-1 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-((1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-27-2 CAPLUS
 CN Piperazine, 1-[(2S)-4-[[4-((2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl)-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910573-28-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-3-furanyl)-1-piperazinyl)ethyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-29-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-3-furanyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910573-32-9 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-4-methyl-2H-pyran-4-yl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-33-0 CAPLUS
 CN Piperazine, 1-[(2S)-4-{4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl}-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(tetrahydro-4-methyl-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




RN 910573-30-7 CAPLUS
 CN Piperazine, 1-[(2S)-4-{4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl}-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910573-31-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-4-methyl-2H-pyran-4-yl)-1-piperazinyl)ethyl] ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910573-37-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-38-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910573-39-6 CAPLUS
 CN Piperazine, 1-[(2S)-4-[(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)-, 4-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-43-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-3-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910573-46-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-47-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910573-44-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-3-yl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-45-4 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910573-48-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-(4-(tetrahydro-3-furanyl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-49-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-(4-(tetrahydro-3-furanyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-50-1 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-51-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-57-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-58-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-52-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-53-4 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-59-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-3-furanyl)-, 4-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-63-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-oxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910573-64-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-3-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-65-8 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-3-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910573-68-1 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-3-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-69-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-3-furanyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910573-66-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-67-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910573-70-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-3-furanyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-71-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-3-furanyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-72-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-4-methyl-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-73-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-4-methyl-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-79-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-80-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-74-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-4-methyl-2H-pyran-4-yl)-1-piperazinyl]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-78-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-82-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-84-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-86-3 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(3-chloro-4-hydroxy-5-methylphenyl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-87-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[[4-(acetyloxy)-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-90-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[[4-(acetyloxy)-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-91-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[4-(formyloxy)-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-88-5 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(3-chloro-4-hydroxy-5-methylphenyl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)-, 4-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-89-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[[4-(formyloxy)-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-92-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[4-(acetyloxy)-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-93-2 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[[4-(formyloxy)-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-94-3 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-(acetyloxy)-3,5-dimethylphenyl]methyl]-1,4-dioxo-6-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-95-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]-1-[[3-chloro-4-(formyloxy)-5-methylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-98-7 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-(acetyloxy)-3-chloro-5-methylphenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-99-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]-1-[[3,5-dibromo-4-hydroxyphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910573-96-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]-1-[[4-(acetyloxy)-3-chloro-5-methylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910573-97-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[3-chloro-4-(formyloxy)-5-methylphenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-00-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-02-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[3,5-dibromo-4-hydroxyphenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-03-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-([3,5-dibromo-4-(formyloxy)phenyl]methyl)-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-04-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-([3,5-dibromo-4-(formyloxy)phenyl]methyl)-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-07-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-([4-(acetyloxy)-3,5-dibromophenyl]methyl)-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-08-2 CAPLUS
 CN Piperazine, 1-((2S)-2-([4-(acetyloxy)-3,5-dibromophenyl]methyl)-1,4-dioxo-4-[4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-05-9 CAPLUS
 CN Piperazine, 1-((2S)-2-([3,5-dibromo-4-(formyloxy)phenyl]methyl)-1,4-dioxo-4-[4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-06-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-([3,5-dibromo-4-(formyloxy)phenyl]methyl)-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-09-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-([3-bromo-4-hydroxyphenyl]methyl)-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-10-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-([3-bromo-4-hydroxyphenyl]methyl)-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-11-7 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(3-bromo-4-hydroxyphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-12-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-15-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-16-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-13-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3-bromo-4-(formyloxy)phenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-14-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(3-bromo-4-(formyloxy)phenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-17-3 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(3,5-dichloro-4-hydroxyphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-18-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN


(Continued)



RN 910574-19-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[3,5-dichloro-4-(formyloxy)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-20-8 CAPLUS

CN Piperazine, 1-[(2S)-2-[[[3,5-dichloro-4-(formyloxy)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN


(Continued)



RN 910574-23-1 CAPLUS

CN Piperazine, 1-[(2S)-2-[[[4-(acetyloxy)-3,5-dichlorophenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-24-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-chloro-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN


(Continued)



RN 910574-21-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[[4-(acetyloxy)-3,5-dichlorophenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-22-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[4-(acetyloxy)-3,5-dichlorophenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-25-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[3-chloro-4-hydroxyphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-26-4 CAPLUS

CN Piperazine, 1-[(2S)-2-[[[3-chloro-4-hydroxyphenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-27-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[3-chloro-4-(formyloxy)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-28-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-[[3-chloro-4-(formyloxy)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-31-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-[[4-(acetyloxy)-3-chlorophenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-32-2 CAPLUS
 CN Piperazine, 1-((2S)-2-[[4-(acetyloxy)-3-chlorophenyl]methyl]-1,4-dioxo-4-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-29-7 CAPLUS
 CN Piperazine, 1-((2S)-2-[[3-chloro-4-(formyloxy)phenyl]methyl]-1,4-dioxo-4-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-30-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(acetyloxy)-3-chlorophenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-33-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[3-chloro-4-(hydroxy-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-34-4 CAPLUS
 CN Piperazine, 1-((2S)-2-[[3-chloro-4-(hydroxy-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-35-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[3-chloro-4-(formyloxy)-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-36-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(acetyloxy)-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-49-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-((1R)-1-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-50-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-47-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-48-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-((1R)-1-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-(tetrahydro-2H-pyran-4-yl)]-1-piperidinyl]butyl)-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-52-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-((1R)-1-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-((1R)-1-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-54-8 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-((1R)-1-[[4-amino-3-methyl-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)-4-(tetrahydro-2H-pyran-4-yl)]-1-piperidinyl]butyl)-4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-56-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(hydroxy-3-methoxy-5-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-57-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(formyloxy-3-methoxy-5-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-61-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(3-ethyl-4-hydroxy-5-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-62-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(3-ethyl-4-hydroxy-5-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-59-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(acetyloxy-3-methoxy-5-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-60-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(3-ethyl-4-hydroxy-5-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-63-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)-, (1R)-1-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-64-0 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)-N-((1R)-1-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-65-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(formyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-66-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(formyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 910574-70-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(formyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-71-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(formyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)

Habe


L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 910574-68-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(formyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-69-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(formyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 910574-72-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(formyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-73-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1R)-1-[[4-(formyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910574-74-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-76-4 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


RN 910574-81-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910574-83-3 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-4-[4-(1,2-dihydro-2-oxo-3(4H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-84-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-, (1R)-1-[[4-hydroxy-3,5-dimethylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Habe


L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 4-[4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-78-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-, (1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.



RN 910574-85-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[(1R)-1-[[4-hydroxy-3,5-dimethylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910574-86-6 CAPLUS
 CN Piperazine, 1-[(2S)-4-[4-(1,2-dihydro-2-oxo-3(4H)-quinazolinyl)-1-piperidinyl]-2-[[4-hydroxy-3,5-dimethylphenyl]methyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-87-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-88-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]-4-(1,2-dihydro-2-oxo-3-quinoliny)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-91-3 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]-N-[(1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]-4-(1,2-dihydro-2-oxo-3-quinoliny)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-92-4 CAPLUS
 CN Piperazine, 1-[(2S)-4-[(1,2-dihydro-2-oxo-3-quinoliny)]-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-89-9 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-4-[(1,2-dihydro-2-oxo-3-quinoliny)]-1-piperidinyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-90-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-93-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-94-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-95-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-([1,7-dimethyl-1H-benzimidazol-5-yl)methyl]-2-oxo-2-[4-((tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-96-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-([2-(dimethylamino)-4-methyl-1H-benzimidazol-6-yl)methyl]-2-oxo-2-[4-((tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-99-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-([3,5-bis(trifluoromethyl)phenyl)methyl]-2-oxo-2-[4-((tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-00-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-([1,2-dihydro-8-methyl-2-oxo-6-quinolinyl)methyl]-2-oxo-2-[4-((tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910574-97-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-([2-methoxy-4-methyl-1H-benzimidazol-6-yl)methyl]-2-oxo-2-[4-((tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910574-98-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-([4-amino-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-((tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-01-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-([1,2-dihydro-1,8-dimethyl-2-oxo-6-quinolinyl)methyl]-2-oxo-2-[4-((tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-02-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-([3,4-dihydro-5-methyl-2H-1,4-benzoxazin-7-yl)methyl]-2-oxo-2-[4-((tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-03-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,4-dihydro-4,5-dimethyl-2H-1,4-benzoxazin-7-yl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-04-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-8-methyl-1,4-benzodioxin-6-yl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 910575-07-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910575-08-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(8-methyl-6-quinolalanyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910575-05-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-7-methyl-2-oxo-1H-benzimidazol-5-yl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-06-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-1,3,7-trimethyl-2-oxo-1H-benzimidazol-5-yl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 910575-10-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-methoxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-11-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3-chloro-5-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-12-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-13-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-16-5 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-17-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-14-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-15-4 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-18-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-19-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-20-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-(acetyloxy)-3,5-dimethylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-7-methoxy-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-21-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(hydroxy-3-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-24-5 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-(hydroxy-3-methylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-25-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-(formyloxy)-3-methylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-22-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(formyloxy)-3-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-23-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-(acetyloxy)-3-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910575-26-7 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-(acetyloxy)-3-methylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-27-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-(hydroxy-3-methylphenyl)methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPIUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910575-28-9 CAPIUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-(formyloxy)-3-methylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-29-0 CAPIUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-(acetyloxy)-3-methylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPIUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910575-32-5 CAPIUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-33-6 CAPIUS
 CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-6-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[(1R)-1-[[4-hydroxy-3,5-dimethylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPIUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910575-30-3 CAPIUS
 CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-6-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[(1R)-1-[[4-(formyloxy)-3-methylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-31-4 CAPIUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-4-[(1,2-dihydro-6-hydroxy-2-oxo-3(4H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPIUS COPYRIGHT 2006 ACS on STM (Continued)



RN 910575-34-7 CAPIUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-4-[(1,2-dihydro-6-hydroxy-2-oxo-3(4H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910575-35-8 CAPIUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-6-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[(1R)-1-[[4-hydroxy-3,5-dimethylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910576-30-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[3-chloro-4-(formyl)-5-methylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910576-31-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[4-(acetyloxy)-3-chloro-5-methylphenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

L4 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




IT 910575-73-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxotetrahydrobenzodiazepinylpiperidines and related compds.)

as CGRP receptor antagonists)

RN 910575-73-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[[3-chloro-5-methyl-4-(phenylmethoxy)phenyl]methyl]-2-oxo-2-[4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2006:1005399 CAPLUS

DOCUMENT NUMBER: 145:377393

TITLE: Preparation of 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines as CGRP receptor antagonists

INVENTOR(S): Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabrice; Dreyer, Alexander; Arndt, Kirsten; Doods, Henri; Schaeuble, Gerhard

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 183pp.

CODEN: P1CKD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100026	A1	20060928	WO 2006-EP2557	20060321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPL. INFO.: WO 2005-EP3094 A 20050323 DE 2004-102004015723A 20040329				
OTHER SOURCE(S): MARPAT 145:377393				
GI				

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [B = substituted Ph, phenols, anilines, etc.; Y = C, N; R3 = cyclopentyl, cyclohexyl, cycloheptyl; R4 = H with provisos] and their pharmaceutically acceptable salts were prepared. For example, benzodiazepinylpiperidine II was prepared from 3-trifluoromethylbenzaldehyde in 7-steps. In CGRP receptor inhibition assays, compds. I exhibited IC50 values ≤ 10000 nM.


IT 866086-78-4P 866086-81-9P 866086-87-5P
 866086-89-7P 910631-30-0P 910631-31-1P
 910631-32-2P 910631-39-9P 910631-49-1P
 910631-52-6P 910631-55-9P 910631-58-2P
 910631-67-3P 910631-68-4P 910631-71-9P
 910631-72-0P 910631-79-7P 910631-80-0P
 910631-87-7P 910631-88-8P 910631-89-9P
 910631-92-4P 910631-93-5P 910631-94-6P
 910631-95-7P 910632-07-4P 910632-08-5P
 910632-09-6P 910632-16-5P 910632-28-9P
 910632-31-4P 910632-34-7P 910632-37-0P
 910632-50-7P 910632-51-8P 910632-54-1P
 910632-56-3P 910632-70-1P 910632-71-2P
 910632-79-0P 910632-80-3P 910632-81-4P
 910632-84-7P 910632-85-8P 910632-86-9P
 910632-87-0P 910632-98-3P 910632-99-4P
 910633-03-3P 910633-18-0P 910633-24-8P
 910633-30-6P 910633-36-2P 910633-54-4P
 910633-55-5P 910633-58-8P 910633-59-9P
 910633-66-8P 910633-67-9P 910633-74-8P
 910633-75-9P 910633-76-0P 910633-79-3P
 910633-80-6P 910633-81-7P 910633-82-8P
 910633-94-2P 910633-97-5P 910634-01-4P
 910634-11-6P 910634-13-8P 910634-16-1P
 910634-20-7P 910634-35-4P 910634-38-7P
 910634-56-9P 910634-60-5P 910634-77-4P
 910634-94-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BLOL (Biological study); PREP (Preparation); USES

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

(Uses)
 (prepn. of oxotetrahydrobenzodiazepinylpiperidines as CGRP receptor antagonists)
 RN 866086-78-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-(4-cyclohexyl-1-piperazinyl)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866086-81-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[(3-(trifluoromethyl)phenyl)methyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-87-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]-1-[(3-(trifluoromethyl)phenyl)methyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866086-89-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910631-30-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-(4-cyclohexyl-1-piperazinyl)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910631-31-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-(4-cyclohexyl-1-piperazinyl)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910631-32-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-((4-cyclopentyl-1-piperazinyl)-1-((3,5-dibromo-4-hydroxyphenyl)methyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910631-39-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-((4-(1-(2-hydroxyethyl)-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910631-55-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-((4-((methylamino)sulfonyl)-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910631-58-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-((4-((dimethylamino)sulfonyl)-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910631-49-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-((4-(1-(methylsulfonyl)-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910631-52-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-((4-((aminosulfonyl)-4-piperidinyl)-1-piperazinyl)-1-((3,5-dibromo-4-hydroxyphenyl)methyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910631-67-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-((4-((methylamino)sulfonyl)-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910631-68-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-((4-((methylamino)sulfonyl)-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910631-71-9 CAPLUS
 CN 1-Piperidinepropanoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1-Piperidinepropanoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 910631-80-0 CAPLUS
 CN 1-Piperidinebutanoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-B




RN 910631-72-0 CAPLUS
 CN 1-Piperidinepropanoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 910631-79-7 CAPLUS
 CN 1-Piperidinebutanoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910631-87-7 CAPLUS
 CN 1-Piperidinebutanoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910631-88-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(hydroxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910631-89-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(methoxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 910631-92-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(ethoxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910631-93-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(ethoxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910631-94-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(ethoxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910631-95-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[(4-[(3-bromo-4-hydroxyphenyl)methyl]cyclohexyl)-1-piperazinyl]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910632-07-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[(4-cyclohexyl-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910632-16-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(1-(2-hydroxyethyl)-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910632-28-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(1-(methylsulfonyl)-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910632-08-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[(4-cycloheptyl-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910632-09-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[(4-cyclopentyl-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910632-31-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-[(1-(2-hydroxyethyl)-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910632-34-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(1-(methylsulfonyl)-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910632-37-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(dimethylamino)sulfonyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910632-50-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(dimethylamino)sulfonyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

PAGE 1-A




PAGE 1-B



RN 910632-56-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(dimethylamino)sulfonyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




Habte

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 910632-51-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(dimethylamino)sulfonyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910632-54-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(dimethylamino)sulfonyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


PAGE 1-B




RN 910632-70-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(dimethylamino)sulfonyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 910632-71-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(dimethylamino)sulfonyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

11/28/2006


L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-γ-oxo- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 910632-79-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(hydroxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910632-80-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(hydroxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910632-81-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(methoxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 910632-84-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[1-[2-(ethoxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 910632-85-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(trans-4-(carboxymethyl)cyclohexyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910632-86-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(cis-4-(2-ethoxy-2-oxoethyl)cyclohexyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910632-87-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 910633-03-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-[(1-(2-hydroxyethyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910633-18-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-[(1-(methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-[4-[(cis-4-(carboxymethyl)cyclohexyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910632-98-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-(4-cycloheptyl-1-piperazinyl)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910632-99-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-(4-cyclopentyl-1-piperazinyl)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 910633-24-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-[(1-(aminosulfonyl)-4-piperidinyl)-1-piperazinyl]-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910633-30-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-[(1-[(methylamino)sulfonyl]-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910633-36-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910633-54-4 CAPLUS
 CN 1-Piperidinepropionic acid, 4-[(1R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 910633-59-9 CAPLUS
 CN 1-Piperidinebutanoic acid, 4-[(1R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910633-55-5 CAPLUS
 CN 1-Piperidineacetic acid, 4-[(1R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910633-58-8 CAPLUS
 CN 1-Piperidinepropionic acid, 4-[(1R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910633-66-8 CAPLUS
 CN 1-Piperidinebutanoic acid, 4-[(1R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910633-67-9 CAPLUS
 CN 1-Piperidinebutanoic acid, 4-[[4-[(2R)-3-(4-hydroxy-3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-γ-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910633-74-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-[1-[2-(hydroxymethyl)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910633-75-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-[1-[2-(hydroxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 910633-76-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-[1-[2-(methoxymethylamino)-2-oxoethyl]-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



RN 910633-79-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[(4-(trans-4-(2-ethoxy-2-oxoethyl)cyclohexyl)-1-piperazinyl)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910633-80-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[(4-(trans-4-(2-ethoxy-2-oxoethyl)cyclohexyl)-1-piperazinyl)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910633-81-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[(4-(trans-4-(2-ethoxy-2-oxoethyl)cyclohexyl)-1-piperazinyl)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910633-82-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[(4-(trans-4-(2-ethoxy-2-oxoethyl)cyclohexyl)-1-piperazinyl)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910633-94-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910633-97-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910634-01-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[(4-(trans-4-(2-ethoxy-2-oxoethyl)cyclohexyl)-1-piperazinyl)-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910634-11-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-[4-[(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910634-13-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-chloro-4-hydroxyphenyl)methyl]-2-[4-[(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910634-35-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-chloro-4-hydroxyphenyl)methyl]-2-[4-[(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910634-38-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3,5-dimethylphenyl)methyl]-2-[4-[(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910634-16-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-chloro-4-hydroxyphenyl)methyl]-2-[4-[(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910634-20-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-chloro-4-hydroxyphenyl)methyl]-2-[4-[(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910634-56-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3,5-dimethylphenyl)methyl]-2-[4-[(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 910634-60-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-[4-[(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)



RN 910634-77-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[4-(1-methylsulfonyl)-4-piperidinyl]-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910634-94-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3-methylphenyl]methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)
 (phenylmethoxy)phenyl]methyl]-2-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 910635-07-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-(1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)




IT 910635-05-1P 910635-06-2P 910635-07-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxotetrahydrobenzodiazepinylpiperidines as CGRP receptor antagonists)

RN 910635-05-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-dimethyl-4-(phenylmethoxy)phenyl]-1-oxo-2-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910635-06-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-dimethyl-4-(phenylmethoxy)phenyl]-1-oxo-2-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM

ACCESSION NUMBER: 2006:656692 CAPLUS

DOCUMENT NUMBER: 145:96491

TITLE: Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
 INVENTOR(S): Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Stenkamp, Dirk; Arndt, Kirsten; Schaenzle, Gerhard; Brückl, Rolf-Stefan

PATENT ASSIGNER(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006069754	A1	20060706	WO 2005-EP13974	20051223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GE, GH, GM, HN, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GE, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, RG, KE, MD, RU, TJ, TH

DE 102004063755 A1 20060720 DE 2004-102004063755 20041229
 US 2006154921 A1 20060713 US 2005-301422 20051213

PRIORITY APPL. INFO.: DE 2004-102004063755A 20041229

AB The invention discloses a method for treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, as well as the use of the active compds. for the manufacture of a pharmaceutical composition intended to be used in this method.

IT 686296-57-1 686296-57-1D, salts 866086-02-4
 866086-02-4D, salts 866086-13-7 866086-13-7D, salts 866086-63-7 866086-63-7D, salts 866086-67-1 866086-67-1D, salts 894071-73-9 894071-73-9D, salts 894071-75-1 894071-75-1D, salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(CGRP antagonists for treatment and prevention of hot flushes in prostate cancer patients)

RN 686296-57-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 686296-57-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866086-02-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 866086-13-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866086-63-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 866086-02-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866086-13-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 866086-63-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866086-67-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)



RN 866086-67-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl] ester (SCI) (CA INDEX NAME)


Absolute stereochemistry.



RN 894071-73-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-methylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)butyl]-4-(1-methyl-4-piperidinyl)- (SCI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)




RN 894071-75-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-methylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)butyl]-4-(1-methyl-4-piperidinyl)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)



RN 894071-73-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-methylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)butyl]-4-(1-methyl-4-piperidinyl)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.



RN 894071-75-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-methylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)butyl]-4-(1-methyl-4-piperidinyl)- (SCI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM

ACCESSION NUMBER: 2006:636811 CAPLUS
 DOCUMENT NUMBER: 145:76714
 TITLE: Use of selected CGRP antagonists for combating menopausal hot flashes
 INVENTOR(S): Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Arndt, Kirsten; Schanzle, Gerhard; Stenkamp, Dirk; Brickl, Rolf-Stefan
 PATENT ASSIGNER(S): Boehringer Ingelheim International GmbH, Germany
 SOURCE: U.S. Pat. Appl., 21 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005142274	A1	20060629	US 2005-301446	20051213
DE 102004063752	A1	20060713	DE 2004-102004063752	20041229
WO 2006072415	A1	20060713	WO 2005-EP13972	20051223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, MA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


PRIORITY APPL. INFO.: DE 2004-102004063752A 20041229
 AB The invention discloses the use of selected CGRP antagonists, the physiol. acceptable salts thereof or the hydrates or the hydrates of the salts thereof for combating menopausal hot flashes. A variety of formations are included.

IT 686296-57-1 686296-57-1D, salts 866086-02-4
 866086-02-4D, salts 866086-13-7 866086-13-7D,
 salts 866086-63-7 866086-63-7D, salts
 866086-67-1 866086-67-1D, salts 894071-73-9
 894071-73-9D, salts 894071-75-1 894071-75-1D,
 salts
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CGRP antagonists for combating menopausal hot flashes)

RN 686296-57-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)butyl]-4-(1-methyl-4-piperidinyl)- (SCI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686296-57-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-02-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-02-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-13-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-13-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-63-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-63-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866086-67-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN


(Continued)



RN 866086-67-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 894071-73-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN


(Continued)



RN 894071-73-9 CAPLUS

CN 1-Piperazine, 1-[(2S)-2-[(3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 894071-75-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN


(Continued)



RN 894071-75-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2006:636805 CAPLUS

DOCUMENT NUMBER: 145:96481

TITLE: Use of selected CGRP antagonists in combination with other antimigraine drugs for the treatment of migraine
INVENTOR(S): Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Arndt, Kirsten; Schenke, Gerhard; Stenkamp, Dirk; Brickl, Rolf-Stefan

PATENT ASSIGNER(S): Boehringer Ingelheim International GmbH, Germany

SOURCE: U.S. Pat. Appl. Publ., 22 pp.

CODES: USKCCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006142273	A1	20060629	US 2005-275169	20051216
DE 102004063753	A1	20060713	DE 2004-102004063753	20041229
WO 2006072413	A1	20060713	WO 2005-KP13964	20051223
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EA, EC, EE, EG, ES, FI, GB, GD, GE, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SS, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO: 1

AB The invention discloses a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, the process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan, or dihydroergotamine, or a physiologically acceptable salt thereof, as well as the corresponding pharmaceutical compositions and the preparation thereof. A variety of formulations are included.

IT 686296-57-1 686296-57-10, salts 866086-02-4 866086-02-40, salts 866086-13-7 866086-13-70, salts 866086-63-7 866086-63-70, salts 866086-67-1 866086-67-10, salts 894071-73-9 894071-73-90, salts 894071-75-1 894071-75-10, salts 894761-30-9 894761-34-3 894761-39-8 894761-40-1 894761-42-3 894761-43-4 894761-44-5 894761-50-3 894761-51-4 894761-52-5 894761-54-7 894761-55-8 894761-57-0 894761-67-2 894761-68-3 894761-69-4 894761-70-7 894761-78-5 894761-82-1 894761-86-5 894761-88-7 894761-93-4 894761-94-5 894761-95-6 894762-03-9 894762-06-2 894762-10-8


L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 894762-14-2 894762-17-5 894762-18-6
 894762-20-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (GCRP antagonists in combination with other antimigraine drugs for
 treatment of migraine)
 RN 686296-57-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-
 methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-
 oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686296-57-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-
 methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-
 oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 866086-13-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-
 benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-
 2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866086-13-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-
 benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-
 2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866086-63-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-
 benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-
 [4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Habte

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 866086-02-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-
 benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-
 (1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866086-02-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-
 benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-
 (1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-63-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-
 benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-
 (1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-67-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-
 benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-
 [4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 866086-67-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 894071-73-9 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 894071-73-9 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 894071-75-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-methylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 894071-75-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-methylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 894761-30-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester, mixt. with 5-chloro-1-[1-[3-(2,3-dihydro-2H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one and 2-[(2,3-dimethylphenyl)amino]benzoic acid (9CI) (CA INDEX NAME)


CN 1

CRN 866086-13-7
 CWF C35 H48 N6 O5

Habte


L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.



CN 2

CRN 57808-66-9
 CWF C22 H24 Cl N5 O2




CN 3

CRN 61-68-7
 CWF C15 H15 N O2

11/28/2006

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 894761-34-3 CAPLUS
 CN 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide, mixt. with 1-[(2S)-2-[[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)piperazine (9CI) (CA INDEX NAME)

CM 1

CRN 894071-73-9
 CMF C36 H46 Cl F3 N6 O4

Absolute stereochemistry.




CM 2

CRN 36322-90-4
 CMF C15 H13 N3 O4 S

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 894761-40-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl] ester, mixt. with 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide (9CI) (CA INDEX NAME)

CM 1

CRN 866086-63-7
 CMF C34 H44 Br2 N6 O5

Absolute stereochemistry.

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 894761-39-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[(cyclohexyloxy)carbonyloxy]ethyl ester, mixt. with 1-[(2S)-2-[[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)piperazine (9CI) (CA INDEX NAME)

CM 1

CRN 894071-73-9
 CMF C36 H46 Cl F3 N6 O4


Absolute stereochemistry.



CM 2


CRN 145040-37-5
 CMF C33 H34 N6 O6

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 364-62-5
 CMF C14 H22 Cl N3 O2




RN 894761-42-3 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)-, mixt. with N,N-dimethyl-5-[(1H-1,2,4-triazol-1-yl)methyl]-1H-indole-3-ethanamine (9CI) (CA INDEX NAME)

CM 1


CRN 894071-73-9
 CMF C36 H46 Cl F3 N6 O4

Absolute stereochemistry.

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 144034-90-0
CMF C15 H19 N5

RN 894761-43-4 CAPLUS
CM 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)methyl)-2-oxo-2-((4-(4-piperidinyl)-1-piperazinyl)ethyl) ester, mixed with 2-chloro-N,N-dimethyl-10H-phenothiazine-10-propanamine and 3-(((2R)-1-methyl-2-pyrrolidinyl)methyl)-5-[2-(phenylsulfonyl)ethyl]-1H-indole (9CI) (CA INDEX NAME)

CM 1

CRN 866086-13-7
CMF C35 H48 N6 O5


Absolute stereochemistry.

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
benzodiazepin-3-yl)-, (1R)-1-((4-hydroxy-3,5-dimethylphenyl)methyl)-2-oxo-2-((4-(4-piperidinyl)-1-piperazinyl)ethyl) ester, mixed with N-methyl-3-((1-methyl-4-piperidinyl)-1H-indol-5-yl)ethanesulfonamide (9CI) (CA INDEX NAME)


CM 1

CRN 866086-13-7
CMF C35 H48 N6 O5

Absolute stereochemistry.



CM 2

CRN 121679-13-8
CMF C17 H25 N3 O2 S

RN 894761-50-3 CAPLUS
CM 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)methyl)-2-oxo-2-((4-(4-piperidinyl)-1-piperazinyl)ethyl) ester, mixed with 2-((2,3-dimethylphenyl)amino)benzoic acid (9CI) (CA INDEX NAME)


CM 1

CRN 866086-13-7
CMF C35 H48 N6 O5

Absolute stereochemistry.

Habte


L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 143322-58-1
CMF C22 H26 N2 O2 S

Absolute stereochemistry. Rotation (+).




CM 3


CRN 50-53-3
CMF C17 H19 Cl N2 S

RN 894761-44-5 CAPLUS
CM 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)methyl)-2-oxo-2-((4-(4-piperidinyl)-1-piperazinyl)ethyl) ester, mixed with 2-chloro-N,N-dimethyl-10H-phenothiazine-10-propanamine and 3-(((2R)-1-methyl-2-pyrrolidinyl)methyl)-5-[2-(phenylsulfonyl)ethyl]-1H-indole (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 61-68-7
CMF C15 H15 N O2


RN 894761-51-4 CAPLUS
CM L-Valine, N-((1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, mixed with 1-[[2S]-2-[[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl)methyl]-1,4-dioxo-4-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)piperazine (9CI) (CA INDEX NAME)

CM 1

CRN 894071-73-9
CMF C36 H46 Cl F3 N6 O4

Absolute stereochemistry.


L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2

CRN 137862-53-4
CMF C24 H29 N5 O3

Absolute stereochemistry.



RN 894761-52-5 CAPLUS
 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester, mist. with (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylate (9CI) (CA INDEX NAME)


CH 1

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CH 1

CRN 866086-63-7
CMF C34 H44 Br2 N6 O5


Absolute stereochemistry.



CH 2

CRN 121679-13-8
CMF C17 H25 N3 O2 S

CH 3


CRN 364-62-5
CMF C14 H22 Cl N3 O2

Habe


L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 866086-63-7
CMF C34 H44 Br2 N6 O5

Absolute stereochemistry.



CH 2

CRN 144689-63-4
CMF C29 H30 N6 O6

RN 894761-54-7 CAPLUS
 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester, mist. with 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide and N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide (9CI)

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CH 1

RN 894761-55-8 CAPLUS
 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester, mist. with 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide monohydrochloride and N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide (9CI) (CA INDEX NAME)


CH 1

CRN 866086-13-7
CMF C35 H48 N6 O5

Absolute stereochemistry.




CH 2

CRN 121679-13-8
CMF C17 H25 N3 O2 S

CH 3

CRN 7232-21-5
CMF C14 H22 Cl N3 O2 . Cl H

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




● HCl

RN 894761-57-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester, mixt. with 2-[(2,6-dichlorophenyl)amino]benzoic acid monosodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 866086-13-7
 CMF C35 H48 N6 O5


Absolute stereochemistry.



CM 2

CRN 15307-79-6
 CMF C14 H11 C12 N O2 . Na

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




RN 894761-68-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, mixt. with 5,5-diphenyl-2,4-imidazolidinedione (9CI) (CA INDEX NAME)

CM 1


CRN 686296-57-1
 CMF C38 H55 N7 O3

Absolute stereochemistry.



CM 2


CRN 57-41-0
 CMF C15 H12 N2 O2



RN 894761-69-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-

Habte

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




● Na

RN 894761-67-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester, mixt. with (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone (9CI) (CA INDEX NAME)

CM 1

CRN 866086-13-7
 CMF C35 H48 N6 O5

Absolute stereochemistry.



CM 2

CRN 139264-17-8
 CMF C16 H21 N3 O2


Absolute stereochemistry.

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 (1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester, compd. with 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-naphthalenediol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 866086-02-4
 CMF C36 H50 N6 O5

Absolute stereochemistry.



CM 2

CRN 42200-33-9
 CMF C17 H27 N O4



RN 894761-70-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester, mixt. with 3-[[[(2R)-1-methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole (9CI) (CA INDEX NAME)


CM 1

CRN 866086-13-7
 CMF C35 H48 N6 O5

11/28/2006

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
Absolute stereochemistry.


(Continued)



CM 2

CRN 143322-58-1
CMF C22 H26 N2 O2 S

Absolute stereochemistry. Rotation (+).



RN 894761-78-5 CAPLUS
CM 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, mixt. with (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl] 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinecarboxylate and 3-[(2R)-1-methyl-2-pyrrolidinylmethyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole (9CI) (CA INDEX NAME)

CM 1

CRN 866086-13-7
CMF C35 H48 N6 O5


Absolute stereochemistry.

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl] ester, mixt. with 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one and N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide (9CI) (CA INDEX NAME)

CM 1


CRN 866086-13-7
CMF C35 H48 N6 O5

Absolute stereochemistry.



CM 2

CRN 121679-13-8
CMF C17 H25 N3 O2 S




CM 3

CRN 57808-66-9
CMF C22 H24 Cl N5 O2

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



CM 2


CRN 143322-58-1
CMF C22 H26 N2 O2 S

Absolute stereochemistry. Rotation (+).




CM 3

CRN 53-86-1
CMF C19 H16 Cl N O4



RN 894761-82-1 CAPLUS

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 894761-86-5 CAPLUS
CM 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl] ester, mixt. with α-methyl-4-(2-methylpropyl)benzeneacetic acid (9CI) (CA INDEX NAME)

CM 1

CRN 866086-13-7
CMF C35 H48 N6 O5


Absolute stereochemistry.



CM 2

CRN 15687-27-1
CMF C13 H18 O2

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




FN	894761-88-7	CAPLUS
CN	1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzoxazin-3-yl)-], (1R)-1-[[4-(hydroxy-3,5-dimethylphenyl)ethyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester, mixt. with 2',6'-difluoro-4-hydroxy[1,1'-biphenyl]-3-carboxylic acid (SCT) (CA INDEX	

CM 1

CPM 866086-02-4
CNP C36 H50 N6 O5


Absolute stereochemistry.



OK 2

CRN 22494-42-4
CMF C13 HB F2 O3

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




● EC1

RN 894761-94-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester, mist. with 3-benzoyl-6-methylbenzenesacetic acid (9CI) (CA INDEX NAME)

CM 1

CRN 866086-02-4
CMP C36 H50 N6 O5

Absolute stereochemistry.




9 2

CRN 22071-15-4
CMT C16 H14 O3

Habte

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 894761-93-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[(4-{1-methyl-4-piperidinyl}-1-piperazinyl)-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, mxt. with 1-[(1-methylethyl)amino]-3-(1-naphthalenyl)propan-2-propanol hydrochloride (9CI) (CA INDEX NAME)

CH 1

· CRN 686296-57-1
CMF C38 H55 N7 O3


Absolute stereochemistry.



OK 2

CRN 318-98-9
CMF C16 H21 N O2 . C1 H

14 ANSWER 5 OF 32 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



```


RN 894761-95-6 CAPLUS
CN 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-,
  carbonylmethyl ester, mixt. with (1R)-1-[(4-hydroxy-3,5-
  dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl
  4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-
  piperidinecarboxylate (9CI) (CA INDEX NAME)

```

CM 1

CRN 866086-13-7
CMF C35 H48 N6 O5

Absolute stereochemistry.




CH 2

CRN 53164-05-9
CHF C21 H18 Cl N O6

11/28/2006

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 894762-03-9 CAPLUS
 CH Piperazine, 1-[(2S)-2-[[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[(4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-1-piperidinyl)-, mixt. with N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide (9CI) (CA INDEX NAME)

CH 1

CRN 894071-73-9
 CHF C36 H46 Cl F3 N6 O4


Absolute stereochemistry.



CH 2

CRN 121679-13-8
 CHF C17 H25 N3 O2 S

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 894762-10-8 CAPLUS
 CH 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl] ester, mixt. with 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (9CI) (CA INDEX NAME)

CH 1


CRN 866086-13-7
 CHF C35 H48 N6 O5

Absolute stereochemistry.




CH 2

CRN 71125-38-7
 CHF C14 H13 N3 O4 S2



Habte

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 894762-06-2 CAPLUS
 CH Benzeneacetic acid, α-methyl-4-(2-methylpropyl)-, mixt. with 1-[(2S)-2-[[3-chloro-4-hydroxy-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[(4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)piperazine (9CI) (CA INDEX NAME)

CH 1

CRN 894071-73-9
 CHF C36 H46 Cl F3 N6 O4

Absolute stereochemistry.



CH 2

CRN 15687-27-1
 CHF C13 H18 O2


L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 894762-14-2 CAPLUS
 CH 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl] ester, mixt. with N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl]benzamide monohydrochloride (9CI) (CA INDEX NAME)

CH 1


CRN 866086-13-7
 CHF C35 H48 N6 O5

Absolute stereochemistry.



CH 2

CRN 38821-52-2
 CHF C22 H25 N3 O . Cl H



● HCl

RN 894762-17-5 CAPLUS
 CH Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt, mixt. with N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinecarboxamide (9CI) (CA INDEX NAME)


CH 1

11/28/2006


L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 686296-57-1
CMF C38 H55 N7 O3

Absolute stereochemistry.



CH 2

CRN 15307-79-6
CMF C14 H11 Cl2 N O2 . Na

● Na

RN 894762-18-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-(4-(4-piperidinyl)-1-piperazinyl)ethyl ester, mixt. with 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (9CI) (CA INDEX NAME)

CH 1

CRN 866086-13-7
CMF C35 H48 N6 O5

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



Absolute stereochemistry.




CH 2

CRN 145040-37-5
CMF C33 H34 N6 O6

PAGE 1-A

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.

CH 2

CRN 169590-42-5
CMF C17 H14 F3 N3 O2 S

RN 894762-20-0 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, 1-[[[(cyclohexyl)carbonyl]oxy]ethyl ester, mixt. with (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinecarboxylate (9CI) (CA INDEX NAME)

CH 1

CRN 866086-63-7
CMF C34 H44 Br2 N6 O5

L4 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L4 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM
 ACCESSION NUMBER: 2006:544646 CAPLUS
 DOCUMENT NUMBER: 145:46084
 TITLE: process for the preparation of
 oxoquinazolinylpiperidinylcarbamoylethylindazoles
 Chaturvedula, Prasad; Han, Xiaojun; Jiang, Xiang-Jun
 INVENTOR(S):
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXK02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006/060678	A2	20060608	WO 2005-US43670	20051202
WO 2006/060678	A3	20060720		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GS, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KN, KP, KR, KS, LC, LE, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, NZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EC, EE, MD, RU, TJ, TN

US 2006122250 A1 20060608 US 2005-291670 20051201
 PRIORITY APPL. INFO.: US 2004-633159P P 20041203
 OTHER SOURCE(S): HARPAT 145:46084
 GI

L4 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)
 IT 890044-53-8P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (process for the preparation of
 oxoquinazolinylpiperidinylcarbamoylethylindazoles)
 RN 890044-53-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-(4-cyclohexyl-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L4 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)



AB Title compds. [I: V = NR1R2, OR4; R4 = alkyl, haloalkyl, etc.; R1, R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, azetidiny, adamantyl, oxadiazolyl, piperazinyl, etc.; R1R2N = (substituted) azetidiny, pyrrolyl, pyrrolinyl, pyrrolidinyl, azepinyl, diazepinyl, piperidinyl, piperazinyl, etc.; R3 = (substituted) (bicyclic) heterocaryl, Ph, fluorenyl, naphthyl; D = O, NCM, alkylsulfonylimino, n = 0-2; A, E = C, N, CH; p = 0, 1; if p = 1, GJE = atoms to form (substituted) (fused) heterocyclyl; if p = 0, AJG = atoms to form (substituted) spirocyclyl; with proviso], were prepared via a 6-step procedure. Thus, 4-iodo-2,6-dimethylaniline hydrochloride (preparation given), Me 2-benzoyloxycarbonylacrylate (preparation given), Pd(OAc)2, Bu4NCl, and Et3N were refluxed together for 3 h in THF to give 65% Me (2)-3-(4-amino-3,5-dimethylphenyl)-2-benzoyloxycarbonylacrylate. This was hydrogenated using (-)-1,2-bis[(2R,5R)-2,5-diethylphospholanol]benzene (cyclooctadiene)rhodium(I) tetrafluoroborate in CH2Cl2/MeOH at 65 psi H2 for 16 h at room temperature to give 98% Me (R)-3-(4-amino-3,5-dimethylphenyl)-2-(benzoyloxycarbonylamino)propanoate. The latter was stirred with KOAc and isoamyl nitrite in PhMe/HOAc for 16 h to give 76% Me (R)-2-(benzoyloxycarbonylamino)-3-(7-methyl-1H-indazol-5-yl)propanoate. Hydrogenolysis of this in MeOH over Pd/C at 15 psi H2 overnight gave 100% Me (R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propanoate. This was stirred with diisopropylethylamine and diisuccinimidyl carbonate in DMF for 30 min, followed by addition of 3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one and stirring for 24 h to give 100% Me (R)-2-[(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamido]-3-(7-methyl-1H-indazol-5-yl)propanoate. Saponification with LiOH in THF/MeOH/H2O followed by acidification with HCl gave 80% free acid, which was stirred with diisopropylethylamine, decahydroisoquinoline, and PyBOP in DMF at 0° to room temperature overnight to give 79% title compound (II).

L4 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM
 ACCESSION NUMBER: 2006:315123 CAPLUS
 DOCUMENT NUMBER: 144:460321
 TITLE: Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepine lead
 Williams, Theresa M.; Stump, Craig A.; Nguyen, Diem N.; Quigley, Amy G.; Bell, Ian M.; Gallicchio, Steven N.; Zartman, C. Blair; Wan, Bang-Lin; Della Penna, Kimberly; Rupanuli, Priya; Kane, Stefanie A.; Koblan, Ken S.; Mosser, Scott D.; Rutledge, Ruth Z.; Salvatore, Christopher; Fay, John F.; Vacca, Joseph P.; Graham, Samuel L.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck & Co., West Point, PA, 19486, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2595-2598
 CODEN: BMCLER; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:460321
 AB High-throughput screening of the Merck sample collection identified a benzodiazepine tetralin-spirohydantoin as a CGRP receptor antagonist with micromolar activity. Comparing the structure of this compound with those of earlier peptide-based antagonists such as BLEN 4096 ES, a key hydrogen bond donor-acceptor pharmacophore was hypothesized. Subsequent structure activity studies supported this hypothesis and led to benzodiazepine piperidinylidihydroquinazolinone, CGRP receptor Ki = 44 nM and IC50 = 38 nM. This compound was orally bioavailable in rats and is a lead in the development of orally bioavailable CGRP antagonists for the treatment of migraine.
 IT 886854-34-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USRS (Uses)
 (non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepine lead in relation to treatment of migraine)
 RN 886854-34-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromophenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 7 OF 32 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 32 CAPIUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2006:55281 CAPIUS
 DOCUMENT NUMBER: 144:205969
 TITLE: Identification and Pharmacological Characterization of Domains Involved in Binding of CGRP Receptor Antagonists to the Calcitonin-like Receptor
 AUTHOR(S): Salvatore, Christopher A.; Mallee, John J.; Bell, Ian M.; Zartman, C. Blair; Williams, Theresa M.; Koblan, Kenneth S.; Kane, Stefanie A.
 CORPORATE SOURCE: Pain Research Medicinal Chemistry, and Biomedical Research Departments, Merck Research Laboratories, West Point, PA, 19486, USA
 SOURCE: Biochemistry (2006), 45(6), 1891-1897
 CODEN: BICHEW; ISSN: 0006-2960
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The calcitonin-like receptor (CLR) and the calcitonin receptor (CTR) interact with receptor activity-modifying protein 1 (RAMP1) at the cell surface to form heterodimeric receptor complexes. CLR and CTR are members of the class II (family B) G-protein-coupled receptors (GPCR) and bind calcitonin gene-related peptide (CGRP) with similar affinities when coexpressed with RAMP1. The observation that various nonpeptide CGRP receptor antagonists display a higher affinity for the CLR/RAMP1 complex than for CTR/RAMP1 provided an opportunity to investigate the mol. determinants of the differential receptor affinities of these antagonists. A chimeric receptor approach was utilized to identify key domains within CLR responsible for conferring high-affinity antagonist binding. Initial chimera expts. implicated distinct regions within CLR as responsible for the affinities of structurally diverse CGRP receptor antagonists. Dissection of these key regions implicated amino acids 37-63 located in the N-terminus of CLR as responsible for the high-affinity interaction of one structural class, while transmembrane domain (TM) 7 was responsible for the interaction of a second class of antagonist. A unique binding interaction in the N-terminus of CLR is consistent with the observation that these compds. also interact with the extracellular region of RAMP1 and could suggest the formation of a binding pocket between the two proteins. Conversely, a compound which interacted with TM7 did not display a similar RAMP1 dependence, suggesting an allosteric mechanism of antagonism. Collectively, these data provide insight into two alternative mechanisms of antagonism for this unique heterodimeric receptor complex.

IT 876066-62-5
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Identification and pharmacol. characterization of domains involved in binding of CGRP receptor antagonists to human calcitonin-like receptor complexed with RAMP1)
 RN 876066-62-5 CAPIUS
 CN 1-Piperidin-4-carboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 32 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 32 CAPIUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1170370 CAPIUS
 DOCUMENT NUMBER: 143:440449
 TITLE: Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-ones and related compounds as cgpr antagonists
 INVENTOR(S): Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenckamp, Dirk; Santagostino, Marco; Palesti, Fabio; Schaezle, Gerhard; Arndt, Kirsten; Doods, Henri
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
 SOURCE: PCT Int. Appl., 294 pp.
 CODEN: PIXKXD
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103037	A2	20051103	WO 2005-EP4104	20050418
WO 2005103037	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, EE, HU, IL, IN, IT, JP, KE, KG, KH, LI, LU, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
DE 102004019492	A1	20051110	DE 2004-102004019492	20040422
US 2005256099	A1	20051117	US 2005-109968	20050420
WO 2006100009	A1	20060928	WO 2006-EP2515	20060318
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
US 2006252931	A1	20061109	US 2006-277177	20060322
PRIORITY APPL. INFO.: DE 2004-102004019492A 20040422				
US 2004-569533P P 20040510				
AR 2005-101139 A 20050323				
WO 2005-EP3094 A 20050323				
WO 2005-EP4104 A 20050418				
EP 2005-21283 A 20050929				

OTHER SOURCE(S): MARPAT 143:440449
 GI

L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [A = O, S; X = O, S; Q = C or N-atom of a heterocyclic ring with provisos; R1 = 5 to 7-membered heterocycle, etc.; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, HCl mediated deprotection of Boc-isindazole II (Z = H) afforded benzodiazepin-2-one II (Z = H) in 72% yield. In human cyp receptor assays, compds. I exhibited IC50 values \leq 1000 nM.

IT 868706-76-7P 868706-80-3P 868706-85-8P
868706-89-2P 868706-92-7P 868706-98-3P
868706-99-4P 868707-08-8P 868707-10-2P
868707-12-4P 868707-13-5P 868707-16-8P
RL: PNC (Pharmacological activity); SPW (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzodiazepin-2-ones and related compds. as cyp antagonists)


RN 868706-76-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-4-methyl-2-oxo-6-benzoxazolyloxy)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 868706-89-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-3,4-dimethyl-2-oxo-6-benzoxazolyloxy)methyl]-2-[(4-[(3-oxo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 868706-80-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-3,4-dimethyl-2-oxo-6-benzoxazolyloxy)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868706-85-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-3,4-dimethyl-2-oxo-6-benzoxazolyloxy)methyl]-2-oxo-2-[(4-(1-(phenylmethyl)-4-piperidinyl)-1-

L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



RN 868706-92-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-3,4-dimethyl-2-oxo-6-benzoxazolyloxy)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868706-98-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-(4-cyclohexyl-1-piperazinyl)-1-[(2,3-dihydro-3,4-dimethyl-2-oxo-6-benzoxazolyloxy)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 868706-99-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-3,4-dimethyl-2-oxo-6-benzoxazoly)methyl]-2-oxo-2-[(4-(tetrahydro-2H-pyran-4-yl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868707-08-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-8-methyl-1,4-benzodioxin-6-yl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 868707-13-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-8-methyl-1,4-benzodioxin-6-yl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



Habte


L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 868707-10-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-8-methyl-1,4-benzodioxin-6-yl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868707-12-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-8-methyl-1,4-benzodioxin-6-yl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 868707-16-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(2,3-dihydro-8-methyl-1,4-benzodioxin-6-yl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



11/28/2006

L4 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2005:1154551 CAPLUS

DOCUMENT NUMBER: 143:422350

TITLE:

Preparation of 1,3-dihydro-3-(4-piperidinyl)-2H-imidazo[4,5-c]quinolin-2-ones and related compounds as cgrp antagonists

INVENTOR(S):

Rudolf, Klaus; Mueller, Stephan Georg; Lustenberger, Philipp; Stenkamp, Dirk; Schaenzle, Gerhard; Arndt, Kirsten; Doods, Henri

PATENT ASSIGNEE(S):

Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG

SOURCE:

PCT Int. Appl., 185 pp.

DOCUMENT TYPE:

CODEN: PIAKXZ

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100352	A1	20051027	WO 2005-EP3759	20050409
WO 2005100352	C1	20060105		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, EE, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004018796	A1	20051103	DE 2004-102004018796	20040415
US 2005250763	A1	20051110	US 2005-107052	20050415
PRIORITY APPL. INFO.:			DE 2004-102004018796A	20040415
			US 2004-569948P	20040511

OTHER SOURCE(S):

MARPAT 143:422350


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = substituted Ph, i.e., CF₃, NH₂, Cl, etc.; X = O, CH₂, NH; R₁ = 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-onyl, 1,3-dihydro-2H-benzimidazol-2-one, etc.; NR₂R₃ = 1,4'-bipiperidinyl, 1-methyl-4-(4-piperidinyl)piperazinyl, 1-(1-methyl-4-piperidinyl)piperazinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, coupling of 1,4'-bipiperidine and acid II afforded imidazo[4,5-c]quinolin-2-one III in 76% yield. In human cgrp receptor assays, compds. I exhibited IC₅₀ values ≤ 1000 nM.

IT 868355-35-5P 868355-38-8P 868355-41-3P


L4 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RW 868355-41-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-(4-(1-methyl-4-piperidinyl)piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); US2S (Uses)

(Prepn. of imidazo[4,5-c]quinolin-2-ones and related compds. as cgrp antagonists)

RW 868355-35-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)-, (1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RW 868355-38-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2005:1152762 CAPLUS

DOCUMENT NUMBER: 143:440448

TITLE:

Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-ones and related compounds as CGRP antagonists

INVENTOR(S):

Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard

PATENT ASSIGNEE(S):

Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE:

Ger. Offen., 51 pp.

DOCUMENT TYPE:

CODEN: GWKXKX

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004018795	A1	20051027	DE 2004-102004018795	20040415
WO 2005100343	A1	20051027	WO 2005-EP3741	20050409
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, EE, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005282857	A1	20051222	US 2005-107195	20050415
PRIORITY APPL. INFO.:			DE 2004-102004018795A	20040415
			US 2004-570005P	20040511

OTHER SOURCE(S):

MARPAT 143:440448

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = substituted Ph, i.e., CF₃, NH₂, Cl, etc.; X = O, CH₂, NH; R₁ = 3,4-dihydro-2(1H)-quinazolinonyl, 1,3,4,5-tetrahydro-2H-benzo-1,3-diazepin-2-onyl; NR₂R₃ = 1,4'-bipiperidinyl, 1-methyl-4-(4-piperidinyl)piperazinyl, 1-(1-methyl-4-piperidinyl)piperazinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, coupling of 4-(2-piperidin-1-yl-ethyl)piperidine and acid II afforded benzodiazepin-2-one III in 64% yield. In human cgrp receptor assays, compds. I exhibited IC₅₀ values ≤ 1000 nM.

IT 868383-61-3P 868383-78-2P 868383-79-3P


868383-80-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); US2S (Uses)

(Preparation of benzodiazepin-2-ones and related compds. as CGRP antagonists)


L4 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 RN 868383-61-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3-chloro-5-(trifluoromethyl)phenyl)methyl]-2-[4-(1-azabicyclo[2.2.2]oct-3-yl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868383-78-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-chloro-3-(trifluoromethyl)phenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868383-79-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-


L4 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 methylphenyl)methyl]-2-(4-cyclopropyl-1-piperazinyl)-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868383-80-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3-chloro-5-methylphenyl)methyl]-2-(4-(1-methylethyl)-1-piperazinyl)-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:1132894 CAPLUS
 DOCUMENT NUMBER: 143:379858
 TITLE: CGRP antagonist in combination with a serotonin reuptake inhibitor for the treatment of migraine or other headache
 INVENTOR(S): Doods, Henri; Rudolf, Klaus
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
 SOURCE: U.S. Pat. Appl. Publ., 13 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005233980	A1	20051020	US 2005-108985	20050419
DE 102004019736	A1	20051117	DE 2004-102004019736	20040420
DE 102004063754	A1	20060713	DE 2004-102004063754	20041229
WO 2005102322	A1	20051103	WO 2005-BP4076	20050418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, CH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BV, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPL. INFO.1
 DE 2004-102004019736A 20040420
 US 2004-570379P P 20040512
 DE 2004-102004063754A 20041229

AB The invention discloses a process for the treatment or prevention of headaches, migraines or cluster headaches, comprising the joint administration of a therapeutically effective amount of a CGRP-antagonist [e.g. 1-[(N2-(3,5-dibromo-N-[(4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl)carbonyl]-D-tyrosyl)-L-lysyl)-4-(4-pyridinyl)piperazine], or a physiol. acceptable salt thereof, and a therapeutically effective amount of the selective serotonin reuptake inhibitor [e.g. (+)-N-methyl-3-(1-naphthoxy)-3-(2-thienyl)propanamine], or a physiol. acceptable salt thereof, as well as the corresponding pharmaceutical compns. and the preparation thereof.


IT 204696-63-9 205061-76-3 205063-65-6
 205063-67-8 205063-68-9 205063-69-0
 205063-87-2 205063-89-4 205064-45-5
 205064-53-5 205064-61-5 205065-28-7
 205065-32-3 205066-02-0 205260-29-3
 205260-30-6 205260-31-7 205260-32-8
 325975-87-9

RL: PAC (Pharmacological activity); TEU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CGRP antagonist combination with serotonin reuptake inhibitor for treatment of migraine or other headache)

RN 204696-63-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-


L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 1H-indazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205061-76-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-65-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habte


11/28/2006

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-67-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[1-methyl-4-piperidinyl]-1-piperazinyl}-2-oxoethyl)-4-[2,3-dihydro-2-oxo-4-(3-thienyl)-1H-imidazol-1-yl]]-9CI] (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-68-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[(4-{[1-methyl-4-piperidinyl]-1-piperazinyl}-2-oxoethyl)-4-[2,3-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-1H-imidazol-1-yl]]-9CI] (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 205063-89-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[1-ethyl-4-piperidinyl]-1-piperazinyl}-2-oxoethyl)-4-[2,3-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-1H-imidazol-1-yl]]-9CI] (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-45-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-[(4-{[1-methyl-4-piperidinyl]-1-piperazinyl}-2-oxoethyl)-4-(1,4-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)]-9CI] (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205063-69-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[1-methyl-4-piperidinyl]-1-piperazinyl}-2-oxoethyl)-4-[2,3-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-1H-imidazol-1-yl]]-9CI] (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-87-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[1-ethyl-4-piperidinyl]-1-piperazinyl}-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-9CI] (CA INDEX NAME)

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-53-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[3-(dimethylamino)propyl]-1-piperazinyl}-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-9CI] (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-61-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[1-methyl-4-piperidinyl]-1-piperazinyl}-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-9CI] (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205065-28-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205065-32-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-[(4-dimethylamino)butyl]phenyl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205260-29-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205260-30-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habte

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

-NH2

RN 205066-02-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-[(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205260-31-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[4-(3-bromophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205260-32-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[2,3-dihydro-4-(3-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 325975-87-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(4-((2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino)-1-oxopropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GM, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 US 2006252750 A1 20061109 US 2006-277175 20060322
 US 2006252931 A1 20061109 US 2006-277177 20060322
 DE 2004-102004015723A 20040329
 US 2004-5663942 P 20040429
 AR 2005-101139 A 20050323
 WO 2005-EP3094 W 20050323
 WO 2005-EP4104 A 20050418
 EP 2005-21283 A 20050929

OTHER SOURCE(S):
 GI

MARPAT 143:367334

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = O, S; X = O, S; D, E = CH, N with provisos; G = CRa; M = CRb; Q = CRc; Ra, Rb, Rc = H, halo, alkyl, etc.; R1 = 5 to 7-membered heterocycle; R2 = H, Ph, pyridinyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, coupling of 1-(1-methylpiperidin-4-yl)piperazine and carboxylic acid II afforded benzodiazepine III in 87% yield. In human OCGRP receptor inhibition assays, compds. I exhibited IC50 values ≤ 10000 nM.

IT 866085-11-2P 866085-27-0P 866085-29-2P
 866085-33-8P 866085-41-8P 866085-47-4P
 866085-54-3P 866085-58-7P 866085-60-1P
 866085-64-5P 866085-68-9P 866085-72-5P
 866085-81-6P 866085-84-9P 866085-90-7P
 866085-96-3P 866085-99-6P 866086-02-4P
 866086-06-8P 866086-10-4P 866086-13-7P
 866086-19-3P 866086-24-0P 866086-26-2P
 866086-30-8P 866086-33-1P 866086-35-3P
 866086-37-5P 866086-41-1P 866086-53-5P
 866086-57-9P 866086-59-1P 866086-63-7P
 866086-67-1P 866086-78-4P 866086-81-9P
 866086-85-3P 866086-87-5P 866086-89-7P
 866087-66-3P 866087-74-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of 3-piperidin-4-yl-tetrahydro-1,3-benzodiazepin-2-ones as OCGRP receptor antagonists)

RN 866085-11-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,4-dibromophenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2005:1075789 CAPLUS
 DOCUMENT NUMBER: 143:367334
 TITLE: Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-ones as OCGRP receptor antagonists
 INVENTOR(S): Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Dreyer, Alexander; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard; Santagostino, Marco; Paleari, Fabio
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
 SOURCE: PCT Int. Appl., 318 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GM, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 102004015723	A1	20051020	DE 2004-102004015723	20040329
CA 2558889	AA	20051006	CA 2005-2558889	20050323
US 2005234067	A1	20051020	US 2005-93834	20050329
WO 2006100009	A1	20060928	WO 2006-EP2515	20060318
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GM, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006100026	A1	20060928	WO 2006-EP2557	20060321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 866085-27-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(4-((2R)-3-(3,4-dibromophenyl)-1-oxo-2-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino)propyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866085-29-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,4-dibromophenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl]ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●2 HCl

RN 866085-33-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,4-dichlorophenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866085-41-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2R)-3-(3,4-dichlorophenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866085-58-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-chloro-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl


RN 866085-60-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habte


L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866085-47-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,4-dichlorophenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 866085-54-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2R)-3-(4-chloro-3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866085-64-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(2R)-3-(3,5-dimethylphenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866085-68-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 866085-72-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(4-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866085-81-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-oxo-2-[(4-(1-phenylmethyl)-4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 866085-96-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-dibromophenyl]methyl]-2-oxo-2-[(4-(1-phenylmethyl)-4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866085-99-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-dibromophenyl]methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




RN 866085-84-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866085-90-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[3,5-dibromophenyl]methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 866086-02-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-hydroxy-3,5-dimethylphenyl]methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-06-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-((1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-hydroxy-3,5-dimethylphenyl]methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-10-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-{1-(phenylmethyl)-4-piperidinyl}-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-13-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-{4-piperidinyl}-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-26-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-{4-piperidinyl}-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-30-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-chloro-4-methylphenyl)methyl]-2-oxo-2-[(4-{4-piperidinyl}-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-19-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-{4-piperidinyl}-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-24-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-{4-piperidinyl}-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-33-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-{4-piperidinyl}-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-35-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-amino-3,5-dimethylphenyl)methyl]-2-oxo-2-[(4-{4-piperidinyl}-1-piperazinyl)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



● 2 HCl

RN 866086-37-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-methylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-41-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3-bromo-4-methylphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 866086-59-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-63-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 866086-53-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-57-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 866086-67-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-78-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(4-cyclohexyl-1-piperazinyl)-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-81-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-85-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866087-66-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866087-74-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866086-87-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866086-89-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCSSION NUMBER: 2005:1050867 CAPLUS
 DOCUMENT NUMBER: 143:347057
 TITLE: Preparation of piperidinecarboxylate derivatives for the treatment of migraines
 INVENTOR(S): Degnan, Andrew P.; Han, Xiaojun; Dubowchik, Gene M.; Macor, John E.; Mercer, Stephen E.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 76 pp.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005215576	A1	20050929	US 2005-91429	20050328
WO 2005095393	A1	20051013	WO 2005-US10330	20050328


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG

PRIORITY APPL. INFO.: US 2004-557408P P 20040329
 OTHER SOURCE(S): MARPAT 143:347057
 GI




AB Comps. of formula I [V = (substituted) MEZ, alkoxy, phenoxy, (substituted) piperidinyl, piperazinyl, etc.; Q = heterocyclmethyl,

L4 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 865626-59-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2-dihydro-2-oxo-3-quinolinyl)-, (1R)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 etc.; D = O, N, NSO2-alkyl; A = C, N, CH, COH; X = (CH2)m; Y = (CH2)n; m, n = 0-2; R = (substituted) oxoquinazolinyl, isoquinolinyl, etc.] are prepd. as antagonists of calcitonin gene-related peptide receptors. The compds. can be used for the treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assoc. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors. Thus, II was prepd. The prepd. compds. had binding affinities of less than 1 nM against human CGRP receptor.

IT 865626-57-9P 865626-58-OP 865626-59-1P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidinecarboxylate derivs. for treatment of migraine)
 RN 865626-57-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2-dihydro-2-oxo-3-quinolinyl)-, (1R)-2-(4-cyclohexyl-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865626-58-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(1,2-dihydro-2-oxo-3-quinolinyl)-, (1R)-2-(4-(4-fluorophenyl)-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCSSION NUMBER: 2005:1004565 CAPLUS
 DOCUMENT NUMBER: 143:306304
 TITLE: Preparation of isindazoles and related compounds as cgrp antagonists
 INVENTOR(S): Lustenberger, Philipp; Rudolf, Klaus; Mueller, Stephan; Georg, Stankamp; Dirk, Doods; Henri, Arndt; Kirsten; Schaeuble, Gerhard
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany;
 SOURCE: Boehringer Ingelheim Pharma GmbH & Co. KG
 PCT Int. Appl., 132 pp.
 CODEN: PIXKX2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005084672	A1	20050915	WO 2005-EP2082	20050226

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG
 DE 102004010254 A1 20050922 DE 2004-102004010254 20040303
 DE 102004028751 A1 20060105 DE 2004-102004028751 20040615
 EP 1722792 A1 20061122 KP 2005-715592 20050226
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU
 US 2005227968 A1 20051013 US 2005-73341 20050303
 PRIORITY APPL. INFO.: DE 2004-102004010254A 20040303
 DE 2004-102004028751A 20040615
 WO 2005-EP2082 W 20050226
 OTHER SOURCE(S): MARPAT 143:306304
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = N, CH; B = N, CH; D = H, Me; E = H, halo, Me, etc.; X = CH2, NH; R1 = (un)substituted 3-phenyl-2-pyrazolin-5-one, tetrahydro-2H-benzo-1,3-diazepin-2-one with proviso] and their pharmaceutically acceptable salts and formulations were prepared. For example, coupling of carboxylic acid II and 1-methyl-4-piperidin-4-ylpiperazine afforded claimed isindazole III in 34% yield. In cgrp antagonist assays, compds. I exhibited IC50 values equal to or < 10000 nM.
 IT 864536-44-7P 864536-45-8P 864536-50-5P
 864536-52-7P 864536-61-8P 864536-62-9P
 864536-67-4P 864536-69-6P 864536-78-7P
 864536-79-8P 864536-84-5P 864536-86-7P
 864536-94-7P 864536-95-8P 864537-00-8P

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


864537-02-0P 864537-09-7P 864537-10-0P
 864537-23-5P 864537-24-6P 864537-33-7P
 864537-34-8P 864537-39-3P 864537-40-6P
 864537-45-1P 864537-46-2P 864537-51-9P
 864537-52-0P 864537-57-5P 864537-58-6P
 864537-63-3P 864537-64-4P 864537-69-9P
 864537-70-2P 864537-75-7P 864537-76-8P
 864537-81-5P 864537-82-6P 864537-87-1P
 864537-88-2P 864537-93-9P 864537-94-0P
 864537-99-5P 864538-00-1P 864538-05-6P
 864538-06-7P 864538-11-4P 864538-12-5P
 864538-17-0P 864538-18-1P 864538-23-8P
 864538-24-9P 864538-29-4P 864538-30-7P
 864538-35-2P 864538-36-3P 864538-41-0P
 864538-42-1P 864538-47-6P 864538-48-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. isindazoles and related compds. as cgrp antagonists medicaments)

RN 864536-44-7 CAPLUS


CN Piperazine, 1-[2-(1H-indazol-5-ylmethyl)-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 864536-45-8 CAPLUS


CN Piperazine, 1-[2-(1H-indazol-5-ylmethyl)-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864536-62-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 864536-67-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-[4-(4-fluorophenyl)-1-piperazinyl]-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864536-69-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864536-50-5 CAPLUS

CN Piperazine, 1-(4-fluorophenyl)-4-[2-(1H-indazol-5-ylmethyl)-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)



RN 864536-52-7 CAPLUS


CN Piperazine, 1-[2-(1H-indazol-5-ylmethyl)-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 864536-61-8 CAPLUS


CN 1-Piperidinecarboxamide, N-[1-(1H-indazol-5-ylmethyl)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864536-78-7 CAPLUS

CN Piperazine, 1-[2-[(7-methyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 864536-79-8 CAPLUS

CN Piperazine, 1-[2-[(7-methyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864536-84-5 CAPLUS


CN Piperazine, 1-(4-fluorophenyl)-4-[2-[(7-methyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)

11/28/2006

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperidinyl]butyl)- (9CI) (CA INDEX NAME)




RN 864536-86-7 CAPLUS
CN Piperazine, 1-[2-[(7-methyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 864536-94-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 864536-95-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864537-00-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 864537-02-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864537-09-7 CAPLUS
CN Piperazine, 1-[4-[4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl]-2-[1H-indazol-5-ylmethyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-10-0 CAPLUS
CN Piperazine, 1-[4-[4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl]-2-[1H-indazol-5-ylmethyl]-1,4-dioxobutyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864537-23-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-[1-[(1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 864537-24-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-[1-[(1H-indazol-5-yl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864537-33-7 CAPLUS
 CN Piperazine, 1-[2-[(7-ethyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-34-8 CAPLUS
 CN Piperazine, 1-[2-[(7-ethyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 864537-45-1 CAPLUS
 CN Piperazine, 1-[2-[(7-bromo-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-46-2 CAPLUS
 CN Piperazine, 1-[2-[(7-bromo-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-51-9 CAPLUS

Habte

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864537-39-3 CAPLUS
 CN Piperazine, 1-[2-[(7-chloro-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-40-6 CAPLUS
 CN Piperazine, 1-[2-[(7-chloro-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Piperazine, 1-[1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]-2-[[7-(trifluoromethyl)-1H-indazol-5-yl]methyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-52-0 CAPLUS
 CN Piperazine, 1-[1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]-2-[[7-(trifluoromethyl)-1H-indazol-5-yl]methyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-57-5 CAPLUS
 CN Piperazine, 1-[2-[(1-methyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864537-58-6 CAPLUS
 CN Piperazine, 1-[2-[(1-methyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-63-3 CAPLUS
 CN Piperazine, 1-[2-[(1,7-dimethyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864537-75-7 CAPLUS
 CN Piperazine, 1-[2-[(7-methyl-1H-benzotriazol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-76-8 CAPLUS
 CN Piperazine, 1-[2-[(7-methyl-1H-benzotriazol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 864537-64-4 CAPLUS
 CN Piperazine, 1-[2-[(1,7-dimethyl-1H-indazol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-69-9 CAPLUS
 CN Piperazine, 1-[2-[(1H-benzotriazol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-70-2 CAPLUS
 CN Piperazine, 1-[2-[(1H-benzotriazol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 864537-81-5 CAPLUS
 CN Piperazine, 1-[2-[(1H-indol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-82-6 CAPLUS
 CN Piperazine, 1-[2-[(1H-indol-5-yl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-87-1 CAPLUS

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Piperazine, 1-[2-[(7-methyl-1H-indol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-88-2 CAPLUS
 CN Piperazine, 1-[2-[(7-methyl-1H-indol-5-yl)methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 864537-93-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(7-ethyl-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 864538-00-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(7-chloro-1H-indazol-5-yl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-05-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(7-bromo-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-06-7 CAPLUS

Habte

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864537-94-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(7-ethyl-1H-indazol-5-yl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864537-99-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(7-chloro-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1-Piperidinecarboxamide, N-[1-[(7-bromo-1H-indazol-5-yl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-11-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[(7-(trifluoromethyl)-1H-indazol-5-yl)methyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-12-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]-1-[(7-(trifluoromethyl)-1H-indazol-5-yl)methyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

11/28/2006


L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864538-17-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(1-methyl-1H-indazol-5-yl)methyl]-2-[(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-18-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(1-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864538-30-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-(1H-benzotriazol-5-ylmethyl)-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-35-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-methyl-1H-benzotriazol-6-yl)methyl]-2-[(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 864538-23-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(1,7-dimethyl-1H-indazol-5-yl)methyl]-2-[(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-24-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(1,7-dimethyl-1H-indazol-5-yl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-29-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-(1H-benzotriazol-5-ylmethyl)-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864538-36-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-methyl-1H-benzotriazol-6-yl)methyl]-2-oxo-2-[(4-(4-piperidinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 864538-41-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-(1H-indol-5-ylmethyl)-2-[(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 864538-42-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(1H-indol-5-yl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 864538-47-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(7-methyl-1H-indol-5-yl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 864538-48-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(7-methyl-1H-indol-5-yl)methyl]-2-oxo-2-[4-

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:638773 CAPLUS

DOCUMENT NUMBER: 143:133401

TITLE: Preparation of diazabicyclics as calcitonin gene related peptide receptor antagonists
 INVENTOR(S): Degnan, Andrew P.; Chen, Ling; Civiello, Rita; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun J.; Macor, John E.; Tora, George
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 385 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065779	A1	20050721	WO 2003-US38799	20031205
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CX, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: BW, GE, GM, GR, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
BY, BG, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
CA 2549330	AA	20050721	CA 2003-2549330	20031205
AU 2003297694	A1	20050812	AU 2003-297694	20031205
EP 1689493	A1	20060816	EP 2003-819270	20031205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
NO 200602648	A	20060802	NO 2006-2648	20060608
PRIORITY APPL. INFO.:			EP 2003-819270	A 20031205
			WO 2003-US38799	W 20031205
OTHER SOURCE(S):	MARPAT 143:133401			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Diazabicyclics I [n, n = 0-2; V = (un)substituted NH₂, OH; Q = (un)substituted alkyl, NH₂, NHC(=O)R, NHC(=O)R₂; U = CH₂, NH; D = O, WCN, alkylsulfonylamino; A = C, N, CH; E = (un)substituted heterocyclic; with proviso] were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). E.g., a multi-step synthesis of II which had IC₅₀ for calcitonin gene related peptide receptor binding of ≤ 10 nM, was given. The pharmaceutical composition comprising the compound I is claimed.

IT 635710-63-3P 635710-64-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRFP

Habte

L4 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (4-piperidinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of diazabicyclics as calcitonin gene related peptide receptor antagonists)


RN 635710-63-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-3-(1H-indazol-5-yl)-1-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 635710-64-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 635710-13-3P 635710-16-6P 635710-44-0P

635710-46-2P 635710-47-3P 635710-65-5P

635710-66-6P 635710-67-7P 635710-68-8P

635710-69-9P 635710-70-2P 635710-71-3P

635710-72-4P 635710-73-5P 635710-74-6P

635710-75-7P 635713-27-8P 635713-29-0P

635713-36-9P 635713-37-0P 773886-35-4P

773886-36-5P 773886-37-6P 773886-38-7P

773886-51-4P 773886-52-5P 773886-69-4P

773886-73-0P 773886-74-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRFP (Preparation); USES (Uses)
 (preparation of diazabicyclics as calcitonin gene related peptide receptor antagonists)

RN 635710-13-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-(1H-indol-5-ylmethyl)-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]-

11/28/2006


L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 635710-16-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-((2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-(1H-indazol-5-yl)methyl]-2-(4-(2-methylpropyl)-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-44-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-(7-methyl-1H-indazol-5-yl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-46-2 CAPLUS


L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-66-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[2-(4-heptyl-1-piperazinyl)-1-(1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-67-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-(4-butyl-1-piperazinyl)-1-(1H-indazol-5-yl)methyl]-2-oxoethyl]-4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[2-(4-ethylhexyl)-1-piperazinyl]-1-(1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-68-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-(1H-indazol-5-yl)methyl]-2-oxo-2-(4-propyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-(7-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 635710-47-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-(7-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 635710-65-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-(1H-indazol-5-yl)methyl]-2-(4-(2-methylbutyl)-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-69-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[2-(4-furanyl-1-piperazinyl)-1-(1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-70-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[2-(4-ethylhexyl)-1-piperazinyl]-1-(1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-71-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-(1H-indazol-5-yl)methyl]-2-oxo-2-(4-(1H-pyrrol-2-yl)methyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RM 635710-72-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-([3-(dimethylamino)-2-propenyl]-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl])-(9CI) (CA INDEX NAME)




RM 635710-73-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-([2-ethyl-3-methylbutyl]-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl])-(9CI) (CA INDEX NAME)




RM 635710-74-6 CAPLUS

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RM 635713-29-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-((2,3-dihydro-2-oxo-6-benzoxazolyl)methyl)-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-(9CI) (CA INDEX NAME)




RM 635713-36-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-((2,3-dihydro-4-methyl-2-oxo-6-benzoxazolyl)methyl)-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-(9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-[(4-(3-phenyl-2-propenyl)-1-piperazinyl)ethyl]]-(9CI) (CA INDEX NAME)




RM 635710-75-7 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-[(4-methyl-1-piperazinyl)-2-oxoethyl]]-(9CI) (CA INDEX NAME)




RM 635713-27-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-((2,3-dihydro-2-oxo-6-benzoxazolyl)methyl)-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-(9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RM 635713-37-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-((4-chloro-2,3-dihydro-2-oxo-6-benzoxazolyl)methyl)-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-(9CI) (CA INDEX NAME)




RM 773886-35-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-((7-methyl-1H-indazol-5-yl)methyl)-2-oxo-2-[(4-phenyl-1-piperazinyl)ethyl]]-(9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 773886-36-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[(4-(4-fluorophenyl)-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 773886-37-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[(4-(2-fluorophenyl)-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 773886-38-7 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[(4-(2-methylphenyl)-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 773886-51-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-(4-cyclohexyl-1-piperazinyl)-1-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 773886-52-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-[(4-(1-methylethyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 773886-69-4 CAPLUS
 CN Piperazine, 1-cyclohexyl-4-[2-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-4-(4-(1,2-dihydro-2-oxo-3(4H)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 773886-73-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-(4-cyclohexyl-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 773886-74-1 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[(4-(4-fluorophenyl)-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 635710-04-2P 635710-06-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of diazoheterocycles as calcitonin gene related peptide receptor antagonists)
 RN 635710-04-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxo-1-[[1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-5-yl]methyl]ethyl]- (9CI) (CA INDEX NAME)



RN 635710-06-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxo-1-[[1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-5-yl]methyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:122798 CAPLUS
 DOCUMENT NUMBER: 142:212404
 TITLE: Use of CGRP antagonists or CGRP release inhibitor in treatment and prevention of hot flushes in prostate cancer patients
 INVENTOR(S): Doods, Henri; Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Hammar, Mats; Spetz, Anna-Clara
 PATENT ASSIGNER(S): Boehringer Ingelheim International GmbH, Germany
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., which
 CODES: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005032783	A1	20050210	US 2004-881892	20040630
CA 2531407	AA	20050120	CA 2004-2531407	20040702
WO 2005004869	A1	20050120	WO 2004-EP7228	20040702

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CE, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GE, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KE, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1648466 A1 20060426 EP 2004-763078 20040702
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPL. INFO.:
 EP 2003-15335 A 20030707
 US 2003-491576P P 20030731
 EP 2003-21802 A 20030926
 US 2003-515817P P 20031030
 WO 2004-EP7228 W 20040702

AB The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a CGRP antagonist and/or of a CGRP release inhibitor to the patient, and to the use of said active compds. for the manufacture of a pharmaceutical composition intended to be used in this method.


IT 204696-61-7 204696-63-9 205061-76-3
 205063-65-6 205063-67-8 205063-68-9
 205063-69-0 205063-87-2 205063-89-4
 205064-45-5 205064-53-5 205064-61-5
 205065-28-1 205065-32-3 205066-02-0
 205260-29-3 205260-30-6 205260-31-7
 205260-32-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients)

RN 204696-61-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-

Habte

L4 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


oxo-4-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204696-63-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205061-76-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-65-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205063-67-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-(3-thienyl)-1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-87-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205063-89-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205063-68-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-69-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-45-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-[[4-(4-acetylphenyl)-1-piperazinyl]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-53-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[[4-(3-(dimethylamino)propyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-61-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[1-methyl-4-piperidinyl]carbonyl}-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205065-28-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[4-methyl-1-piperazinyl]carbonyl}-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

-NMe2

RN 205066-02-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(5-methoxy-4-pyrimidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205260-29-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl}-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205065-32-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[4-(dimethylamino)butyl]phenyl}-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205260-30-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl}-1-piperazinyl)-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205260-31-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl}-1-piperazinyl)-2-oxoethyl]-4-[4-(3-bromophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RM 205260-32-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-[(3-oxo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-4-(3-methoxyphenyl)-2-oxo-1H-imidazol-1-yl)-9CI] (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(un)substituted alkyl, NH₂, NHCO₂H, NHCONH₂, U = CH₂, NH, D = O, NCM, alkylsulfonylimino; A = C, N, CH₂; E = (un)substituted heterocyclic; with proviso) were prepd. for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing assocd. with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepd. from 1H-indazole-5-carboxaldehyde and had IC₅₀ for calcitonin gene related peptide receptor binding of ≤ 10 nM. The pharmaceutical compn. comprising the compd. I is claimed.

IT 635710-63-3P 635710-64-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)


RM 635710-63-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-3-(1H-indazol-5-yl)-1-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RM 635710-64-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 635710-13-3P 635710-16-6P 635710-44-0P
635710-46-2P 635710-47-3P 635710-65-5P
635710-66-6P 635710-67-7P 635710-68-8P
635710-69-9P 635710-70-2P 635710-71-3P
635710-72-4P 635710-73-5P 635710-74-6P


Habe

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857166 CAPLUS
DOCUMENT NUMBER: 141:332218
TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists
INVENTOR(S): Chaturvedula, Prasad V.; Chen, Ling; Clivello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Tora, George; Vig, Shikha
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 203 pp., Cont.-in-part of U.S. Ser. No. 445,523.
CODING: USXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204397	A1	20041014	US 2003-729155	20031205
US 2004063735	A1	20040401	US 2003-445523	20030527
PRIORITY APPLN. INFO.:			US 2002-386138P	P 20020605
			US 2002-388617P	P 20020613
			US 2002-389870P	P 20020619
			US 2002-393200P	P 20020701
			US 2002-413534P	P 20020925
			US 2003-445523	A2 20030527

OTHER SOURCE(S): MARPAT 141:332218
GI




AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH₂, CH₂, Q =]

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

635710-75-7P 635713-27-8P 635713-29-0P
635713-36-9P 635713-37-0P 773886-35-4P
773886-36-5P 773886-37-6P 773886-38-7P
773886-51-4P 773886-52-5P 773886-69-4P
773886-73-0P 773886-74-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazaheterocycles as calcitonin gene related peptide receptor antagonists)


RM 635710-13-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-(1H-indol-5-ylmethyl)-2-[(4-(2-methylpropyl)-1-piperazinyl)-2-oxoethyl]-9CI] (CA INDEX NAME)



RM 635710-16-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-(1H-indol-5-ylmethyl)-2-[(4-(2-methylpropyl)-1-piperazinyl)-2-oxoethyl]-9CI] (CA INDEX NAME)




RM 635710-44-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-9CI] (CA INDEX NAME)

11/28/2006


L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 635710-46-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-((7-methyl-1H-indazol-5-yl)methyl)-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 635710-47-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-((7-methyl-1H-indazol-5-yl)methyl)-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-68-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-((1H-indazol-5-yl)methyl)-2-oxo-2-(4-propyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 635710-69-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-((4-(2-furanylmethyl)-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-70-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-((4-(2-ethylhexyl)-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 635710-65-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-((1H-indazol-5-ylmethyl)-2-oxo-2-(4-(2-methylbutyl)-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-66-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-(4-heptyl-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-67-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-(4-butyl-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]-4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-71-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-((1H-indazol-5-yl)methyl)-2-oxo-2-(4-(1H-pyrrol-2-ylmethyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 635710-72-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-((4-(3-(dimethylamino)-2-propenyl)-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-73-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-((1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-((4-(2-ethyl-3-methylbutyl)-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 635710-74-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-[4-(3-phenyl-2-propenyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 635710-75-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-[4-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635713-27-8 CAPLUS

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635713-37-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(4-chloro-2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 773886-35-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-[4-(phenyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 1-Piperidinecarboxamide, N-[1-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 635713-29-0 CAPLUS


CN 1-Piperidinecarboxamide, N-[1-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 635713-36-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[1-[(2,3-dihydro-4-methyl-2-oxo-6-benzoxazolyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 773886-36-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 773886-37-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[4-(2-fluorophenyl)-1-piperazinyl]-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 773886-38-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[4-(2-fluorophenyl)-1-piperazinyl]-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Hatte


11/28/2006

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[(2-methylphenyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 773886-51-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-(4-cyclohexyl-1-piperazinyl)-1-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-oxoethyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 773886-52-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-[(4-(1-methylethyl)-1-piperazinyl)-2-oxoethyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 773886-74-1 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[(4-(4-fluorophenyl)-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




IT 635710-04-2P 635710-06-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635710-04-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[2-[(4-(2-methylpropyl)-1-piperazinyl)-2-oxo-1-[[1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-5-yl]methyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 773886-69-4 CAPLUS
 CN Piperazine, 1-cyclohexyl-4-[2-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-4-[(4-(1,2-dihydro-2-oxo-3(4H)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)




RN 773886-73-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-(4-cyclohexyl-1-piperazinyl)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxoethyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-06-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[2-[(4-(2-methylpropyl)-1-piperazinyl)-2-oxo-1-[[1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indazol-5-yl]methyl]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 2004:587914 CAPLUS
DOCUMENT NUMBER: 141:140319
TITLE: Preparation of amino acid dipiperidides as CGFR antagonists
INVENTOR(S): Bauer, Eckhart; Gerlach, Kai; Burnaus, Rudolf; Mueller, Stephan; Rudolf, Klaus; Schindler, Marcus; Stenkamp, Dirk
PATENT ASSIGNER(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
SOURCE: Ger. Offen., 98 pp.
COUNTRY: ~~GERMANY~~
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10300973	A1	20040722	DE 2003-10300973	20030114
AU 2004203916	A1	20040729	AU 2004-203916	20040109
CA 2513132	AA	20040729	CA 2004-2513132	20040109
WO 2004063171	A1	20040729	WO 2004-EP87	20040109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CI, CN, CO, CR, CU, CZ, DK, DM, EE, EC, EG, ES, FI, GB, GD, GE, GR, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LU, MA, MD, ME, MG, MK, MN, MU, MZ, NA, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, SZ, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, YU, ZA, ZM, ZW				
EP 1587795	A1	20051026	EP 2004-700987	20040109
R: AT, BR, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, TR, BG, CZ, KR, HU, SK				
BR 2004006562	A	20051220	BR 2004-6762	20040109
JP 1739805	A	20060222	CN 2004-80002209	20040109
JP 20060615875	T2	20060628	JP 2006-50077	20040109
US 2004192729	A1	20040930	US 2004-755593	20040112
NO 2005003794	A	20050810	NO 2005-3794	20050810
PRIORITY APPL. INFO.:				
			DE 2003-10300973	A 20030114
			US 2003-443492P	P 20030129
			WO 2004-EP87	W 20040109


OTHER SOURCE(S): MARPAT 141:140319
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted diaza-, triaza-, 5,5-dioxidothiadiazaheterocycles; Ar = (un)substituted aryl-, heteroaryl Y = CH₂, NH; Y1 = (un)substituted CH₂, N; R1 = (un)substituted N heterocycles; R2, R3 = H, carboxylic ester] were prepared for use as CGRP antagonists in the production and purification of antibodies and as marked compds. in RIA and ELISA assays and as diagnostic or analytic additives in neurotransmitter research (no date). Thus, the piperidine II was prepared from the amino acid and piperidine fragments in a multi-step synthesis.

IT 726183-11-5F 726183-13-7F 726183-25-1F
R1c_PAC [Pharmacological activity]; RCT [Reagent]; SPN [Synthetic

L4 ANSWER 19 OF 32 CAPIUS COPYRIGHT 2006 ACS on STN (Continued)
CN 726183-25-1 CAPIUS
R1 1-Piperidineacetic acid, 4-{4-[3-(4-bromo-3,5-dimethylphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl}-ethyl ester (9CI) (CA INDEX NAME)



325975-87-89	726183-08-09	726183-12-28
726183-14-16	726183-15-15	726183-18-69
726183-32-07	726183-59-11	726183-60-48
726183-64-87	726183-66-07	726183-67-14
726183-70-60	726183-72-87	726183-73-99
726183-78-47	726183-80-87	726183-81-99
726183-84-22	726183-88-66	726183-89-78
726183-90-09	726183-91-11	726183-93-33
726183-94-47	726183-95-59	726183-96-69
726183-97-77	726183-98-82	726184-27-69
726184-05-78	726184-06-78	726184-08-09
726184-41-47	726184-42-59	726184-44-47
726184-45-87	726184-46-99	726184-47-07
726184-49-29	726184-51-62	726184-52-78
726184-53-87	726184-54-99	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RW 325975-87-9 CAPIWS
 CN 1-Piperidineacetic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,6-di-hydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxo-6-oxo-1,1-piperazinyl]-9(1CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
preparation); TEU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of amino acid dipiperides as CGRP antagonyists)
RN 726183-11-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[(4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-
[[[(4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-
2-oxopropyl]-3-piperidinyl], ethyl ester, cit- [9CI] (CA INDEX NAME)

Absolute stereochemistry.




RN 726183-13-7 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-
 [[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-
 1-oxopropyl]-1-piperazinyl]-ethyl ester, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-08-0 CAPIUS
 CN 1-Piperidinacetic acid, 4-[4-[(2R)-3-(3,5-dibromo-4-carboxyphenyl)-2-[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)

PAGE 1-B

-OBu-t

RN 726183-12-6 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 726183-14-8 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




RN 726183-32-0 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[4-[(2R)-3-(4-bromo-3,5-dimethylphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 726183-59-1 CAPLUS
 CN Benzoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 726183-15-9 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-18-2 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 726183-60-4 CAPLUS
 CN Benzoic acid, 3-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-64-8 CAPLUS
 CN Benzoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-3-(trifluoromethyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-66-0 CAPLUS
 CN Benzoic acid, 4-[[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-67-1 CAPLUS
 CN Benzoic acid, 3-[[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-73-9 CAPLUS
 CN Benzoic acid, 3-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-78-4 CAPLUS
 CN Benzoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-70-6 CAPLUS
 CN Benzoic acid, 4-[[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-1-piperazinyl]-3-(trifluoromethyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-72-8 CAPLUS
 CN Benzoic acid, 4-[[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-80-8 CAPLUS
 CN Benzoic acid, 4-[[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-81-9 CAPLUS
 CN Benzoic acid, 3-[[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-84-2 CAPLUS
 CN Benzoic acid, 4-[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]amino]propyl]-1-piperazinyl]-3-(trifluoromethyl)-1-oxopropyl]-1-piperazinyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-88-6 CAPLUS
 CN 5-Thiazolecarboxylic acid, 2-[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-91-1 CAPLUS
 CN 2-Thiazolecarboxylic acid, 4-[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-93-3 CAPLUS
 CN 2-Thiazolecarboxylic acid, 4-[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-89-7 CAPLUS
 CN 2-Thiazolecarboxylic acid, 4-[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-90-0 CAPLUS
 CN 5-Thiazolecarboxylic acid, 2-[4-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-94-4 CAPLUS
 CN 5-Thiazolecarboxylic acid, 2-[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 726183-95-5 CAPLUS
 CN 2-Thiazolecarboxylic acid, 4-[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 726183-96-6 CAPIUS
CN 5-Thiazolecarboxylic acid, 2-[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 726183-97-7 CAPLUS
CN 1-Piperidineacetic acid, 4-[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726184-36-7 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-[2-[(3,4-dibromophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1-[1-methyl-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 726184-38-9 CAPLUS
CN 2-Piperazinecarboxylic acid, 4-[2-[(3,5-dibromo-4-methylphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dimethyl]-1-(1-dicyclo-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726183-98-8 CAPLUS
 CN 1-Piperidineacetic acid, 4-[4-[(2R)-3-(4-amino-3,5-dibromophenyl)-1-oxo-2-
 [[[(4-1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-
 piperidinyl]carbonyl]amino]propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 726184-27-6 CAPIUS
CN 1-Piperidineacetic acid, 4-{4-[2-[(3,4-dibromophenyl)methyl]-4-{4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1-piperazinyl}- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726184-39-0 CAPIUS
CN 2-Piperazinecarboxylic acid, 1-[2-[(3,4-dibromophenyl)methyl]-4-{4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl}-1,4-dioxabutyl]-4-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 726184-41-4 CAPLUS
CN 2-Piperazinecarboxylic acid, 4-[2-[(3,4-dibromophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1-[1-methyl-4-piperidinyl]- (9CI) (CA INDEX NAME)

11/28/2006

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726184-42-5 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-[2-[(3,4-dibromophenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 726184-44-7 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-[2-[(3,5-dibromo-4-methylphenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726184-45-8 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-[2-[(3,5-dibromo-4-methylphenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 726184-46-9 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-[2-[(4-amino-3,5-dibromophenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726184-47-0 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-[2-[(4-amino-3,5-dibromophenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 726184-49-2 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-[2-[(4-amino-3,5-dibromophenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726184-51-6 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-[2-[(4-amino-3,5-dibromophenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 726184-52-7 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-[2-[(4-amino-3,5-dibromophenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)



RN 726184-53-8 CAPLUS

CN 2-piperazinecarboxylic acid, 4-[(4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-1-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 726184-54-9 CAPLUS

CN 2-piperazinecarboxylic acid, 1-[(4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)

Own work

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM

ACCESSION NUMBER:

2004:370923 CAPLUS

DOCUMENT NUMBER:

140:391302

TITLE:

Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches

INVENTOR(S):

Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Arndt, Kirsten; Doods, Henri

PATENT ASSIGNEE(S):

Boehringer Ingelheim, Germany

SOURCE:

PCT Int. Appl., 254 pp.

DOCUMENT TYPE:

CODEN: P1XK02

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037811	A1	20040506	WO 2003-EP11763	20031023
WO 2004037811	C1	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, GU, HK, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, NI, NO, NP, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW, ZY				
RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
DE 10250082	A1	20040513	DE 2002-10250082	20021025
US 2004132716	A1	20040708	US 2003-68921	20031015
CA 2503462	AA	20040506	CA 2003-2503462	20031023
AU 2003276157	A1	20040513	AU 2003-276157	20031023
EP 1558601	A1	20050803	EP 2003-809310	20031023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015642	A	20050830	BR 2003-15642	20031023
CN 1708492	A	20051214	CN 2003-80101980	20031023
JP 2006050573	T2	20060216	JP 2004-545964	20031023
ZA 2005002247	A	20050919	ZA 2005-2247	20050317
NO 2005002493	A	20050524	NO 2005-2493	20050524
PRIORITY APPL. INFO.:				
		DE 2002-10250082	A	20021025
		US 2002-426167P	P	20021114
		WO 2003-EP11763	W	20031023

OTHER SOURCE(S):

MARPAT 140:391302


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S, substituted imino, etc.; Y, Z = alkyl, difluoromethyl, trifluoromethyl, etc.; R1 = 5-7 membered aza, diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For

Habte

L4 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)



L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STM (Continued)

example, benzo-1,3-diazepin-2-one II was prepd. from 1-(3,4-diethylphenyl)ethanone in 8-steps. In human CGRP receptor binding affinity assays, compds. I exhibited IC50 values < 10000 nM. Compds. I are claimed useful for the treatment of migraine headaches.


IT

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RMT (Reactant or reagent); USES (Uses) (preparation of benzo-1,3-diazepin-2-ones and related compds. as CGRP receptor antagonists for the treatment of migraine headaches)

RN 686297-05-2 CAPLUS

CN 1-piperidinecarboxamide, N-[(1R)-2-oxo-2-[(4-[1-(phenylmethyl)-4-piperidinyl]-1-piperazinyl)-1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT

686296-57-1P 686296-62-8P 686296-64-0P
686296-72-0P 686296-73-1P 686296-74-2P
686296-76-4P 686296-77-5P 686296-79-7P
686296-80-0P 686296-81-1P 686296-82-2P
686296-86-6P 686296-90-2P 686296-97-9P
686296-98-0P 686297-04-1P 686297-07-4P
686297-09-6P 686297-12-1P 686297-15-4P
686297-30-3P 686297-36-9P 686297-39-2P
686297-56-3P 686297-59-6P 686297-60-9P
686297-73-4P 686297-78-9P 686297-88-1P
686297-89-2P 686745-32-4P 686745-33-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzo-1,3-diazepin-2-ones and related compds. as CGRP receptor antagonists for the treatment of migraine headaches)


RN 686296-57-1 CAPLUS

CN 1-piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

11/28/2006

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 686296-62-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 686296-64-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686296-74-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686296-76-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-thieno[3,4-d]pyrimidin-3(4H)-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686296-72-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686296-73-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686296-77-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-thieno[3,2-d]pyrimidin-3(2H)-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686296-79-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3H-thieno[3,4-d]-1,3-diazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686296-80-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-thieno[3,2-d]-1,3-diazepin-3-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686296-81-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-thieno[2,3-d]-1,3-diazepin-3-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686296-82-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxothieno[2,3-d]pyrimidin-3(2H)-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686296-86-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686296-90-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686296-97-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-oxo-2-[4-(trifluoroacetyl)phenyl]-1-piperazinyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686296-98-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-oxo-2-(4-(4-piperidinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686297-04-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686297-07-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]-1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686297-09-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 686297-30-3 CAPLUS
 CN Piperazine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(3,4-dimethylphenyl)methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 686297-36-9 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(3,4-dimethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 686297-12-1 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-N-[(1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 686297-15-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 686297-39-2 CAPLUS
 CN Piperazine, 1-[2-[(3,4-diethylphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 686297-56-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686297-59-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(3,4-diethylphenyl)methyl]-1,4-dioxo-4-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686297-60-9 CAPLUS
 CN Piperazine, 1-[(2S)-2-[(3,4-diethylphenyl)methyl]-1,4-dioxo-4-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 686297-88-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CH 1

CRN 686296-57-1
 CMF C38 H55 N7 O3

Absolute stereochemistry.




CH 2

CRN 110-16-7
 CMF C4 H6 O4

Double bond geometry as shown.


Habte

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686297-73-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-ethyl-3-(trifluoromethyl)phenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 686297-78-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3-ethyl-4-(trifluoromethyl)phenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 686297-89-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CH 1

CRN 686296-57-1
 CMF C38 H55 N7 O3

Absolute stereochemistry.



CH 2

CRN 98-11-3
 CMF C6 H6 O3 S




RN 686745-32-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 686745-33-5 CAPLUS
 CN Piperazine, 1-[[2R]-2-[[[(cyanoamino)[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]methyl]amino]-3-(3,4-diethylphenyl)-1-oxopropyl]-4-(1-methyl-4-piperidinyl)]- (SCI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:370922 CAPLUS
 DOCUMENT NUMBER: 140:391301
 TITLE: Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches
 INVENTOR(S): Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Kirsten, Arndt; Doods, Henri
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 315 pp.
 CODES: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037810	A1	20040506	WO 2003-EP11762	20031023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, NU, TJ, TH, AT, BE, BG, CH, CI, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10250080	A1	20040513	DE 2002-10250080	20021025
US 2006079504	A1	20060413	US 2003-687262	20031016
CA 2503455	AA	20040506	CA 2003-2503455	20031023
AU 2003276156	A1	20040513	AU 2003-276156	20031023
EP 1558600	A1	20050803	EP 2003-809317	20031023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015665	A	20050830	BR 2003-15665	20031023
CN 1708493	A	20051214	CN 2003-80102004	20031023
JP 2006516244	T2	20060629	JP 2004-545963	20031023
NO 2005002496	A	20050624	NO 2005-2496	20050524
PRIORITY APPL. INFO.:				
OTHER SOURCE(S): HARPAT 140:391301				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S, substituted imino, etc.; U = alkyl, alkenyl, alkynyl, etc.; V = Cl, Br,

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 amino, etc.; W = H, halo, difluoromethyl, etc.; R1 = 5-7 membered azo, diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepd. For example, benzo-1,3-diazepin-2-one II was prepd. from 4-amino-3-chloro-5-(trifluoromethyl)benzoic acid in 9-steps. In human CGRP receptor binding affinity assays, compds. I exhibited IC50 values < 10000 nM. Compds. I are claimed useful for the treatment of migraine headaches.


IT 688018-15-7P 688018-22-6P 688018-27-1P
 688018-35-1P 688018-39-5P 688018-63-5P
 688018-65-7P 688018-98-6P 688019-07-0P
 688019-08-1P 688019-15-0P 688019-23-0P
 688019-24-1P 688019-30-9P 688019-37-6P
 688019-40-1P 688019-43-4P 688019-47-8P
 688019-53-6P 688019-64-9P 688019-67-2P
 688019-70-7P 688019-76-3P 688019-79-6P
 688019-86-5P 688019-88-7P 688019-97-8P
 688019-99-0P 688044-92-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzo-1,3-diazepin-2-ones and related compds. as CGRP receptor antagonists for the treatment of migraine headaches)

RN 688018-15-7 CAPLUS
 CN Piperazine, 1-[[2-[[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-pyridinyl]]- (SCI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688018-22-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-pyridinyl]]- (SCI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 688018-27-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-pyridinyl]]- (SCI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688018-35-1 CAPLUS
 CN Piperazine, 1-[[2S]-2-[[[4-amino-3-bromo-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-pyridinyl)]- (SCI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 688018-39-5 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-bromo-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688018-63-5 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-pyridinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 688019-07-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688019-08-1 CAPLUS
 CN 1-Piperazine-sulfonamide, 4-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-N-(1-methyl-4-piperidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 688018-65-7 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-phenylmethyl-4-piperidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688018-98-6 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 688019-15-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(4-(trifluoroacetyl)phenyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688019-23-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3,5-bis(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 688019-24-1 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[4-amino-3,5-bis(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-azabicyclo[2.2.2]oct-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 688019-30-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(1R)-1-[[4-amino-3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 688019-43-4 CAPLUS
 CN 1-Piperidineacetic acid, 4-[(4-[3-(4-bromo-3-methylphenyl)-2-[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 688019-47-8 CAPLUS
 CN Piperazine, 1-[2-[[4-bromo-3-methylphenyl]methyl]-4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-[(4-[3-(dimethylamino)propyl]phenyl)- (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 688019-37-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-bromo-3-methylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 688019-40-1 CAPLUS
 CN 1-Piperidineacetic acid, 4-[(4-[3-(4-bromo-3-methylphenyl)-2-[[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 688019-53-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-chloro-3-methylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 688019-64-9 CAPLUS
 CN Piperazine, 1-[2-[[4-chloro-3-methylphenyl]methyl]-4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 688019-67-2 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-[2-[[4-chloro-3-methylphenyl]methyl]-4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)

11/28/2006

L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 688019-70-7 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-[2-[(4-chloro-3-methylphenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1-(1-methyl-4-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 688019-76-3 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-[2-[(4-chloro-3-methylphenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 688019-88-7 CAPLUS
 CN Piperazine, 1-[2-[(3-bromo-4-chloro-5-methylphenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 688019-97-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3-bromo-4-chloro-5-methylphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 688019-79-6 CAPLUS
 CN Piperazine, 1-[2-[(4-chloro-3-methylphenyl)methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 688019-86-5 CAPLUS
 CN Piperazine, 1-[2-[(3-bromo-4-chloro-5-methylphenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 688019-99-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3-bromo-4-chloro-5-methylphenyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 688044-92-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1,4-dioxo-4-[(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]butyl]-4-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:2675 CAPLUS
 DOCUMENT NUMBER: 140:65199
 TITLE: Preparations for the intranasal application of selected CGRP antagonists derived from amino acids and a method for their production
 INVENTOR(S): Kruss, Bernd; Gaiser, Marc A.; Busch, Ulrich; Jost, Klaus
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PEXK22
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACT. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000289	A2	20031231	WO 2003-EP6156	20030612
WO 2004000289	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HN, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TH, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GE, GW, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, EE, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TH, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
DE 10227294	A1	20040108	DE 2002-10227294	20020619
CA 2487716	AA	20031231	CA 2003-2487716	20030612
AU 2003246414	A1	20040106	AU 2003-246414	20030612
EP 1517674	A2	20050330	EP 2003-760605	20030612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200530830	T2	20051013	JP 2004-514694	20030612
US 2004076587	A1	20040422	US 2003-463063	20030617
US 2006193786	A1	20060831	US 2006-419219	20060519
PRIORITY APPL. INFO.:				
DE 2002-10227294 A 20020619				
US 2002-395184P P 20020711				
WO 2003-EP6156 W 20030612				
US 2003-463063 A1 20030617				

AB The invention relates to pharmaceutical compns. for nasal application, comprising selected CGRP antagonists, which are described in WO 98/11128, in addition to a method for their production. Thus an aqueous solution with 10 mg drug and 1.75 mol-equivalent HCl contained: BIEN 4096 10 mg; 1N HCl 20.45 mg; mannitol 6 mg; water to 0.1 mL.

IT 204696-61-7 204696-63-9 205061-76-3
 205063-65-6 205063-67-8 205063-68-9
 205063-69-0 205063-87-2 205063-89-4
 205064-45-5 205064-53-5 205064-61-5
 205065-28-7 205065-32-3 205066-02-0
 205260-29-3 205260-30-6 205260-31-7
 205260-32-8


L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 205061-76-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3-phenyl-1H-imidazol-1-yl)]-9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205063-65-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)]-9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-67-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-(3-thienyl)-1H-imidazol-1-yl)]-9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habte


L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preps. for intranasal application of selected CGRP antagonists derived from amino acids and prodn. method)
 RN 204696-61-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)]-9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204696-63-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)]-9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 205063-68-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]]-9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-69-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-87-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-ethyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-9CI] (CA INDEX NAME)


Absolute stereochemistry.



RN 205063-89-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-9CI] (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-61-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-9CI] (CA INDEX NAME)


Absolute stereochemistry.



RN 205065-28-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(4-methyl-1-piperazinyl)carbonyl}-1-piperazinyl)-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-9CI] (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-45-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-[(4-(4-acetylphenyl)-1-piperazinyl)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)]-9CI] (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-53-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[3-(dimethylamino)propyl]-1-piperazinyl}-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-9CI] (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205065-32-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{[4-(dimethylamino)butyl]phenyl}-1-piperazinyl)-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-9CI] (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

PAGE 1-B

-NMe2

RN 205066-02-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205260-29-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.




RN 205260-32-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[(2,3-dihydro-4-(3-methoxyphenyl)-2-oxo-1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 205260-30-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[(2,3-dihydro-2-oxo-4-[(3-trifluoromethyl)phenyl]-1H-imidazol-1-yl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205260-31-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[(2,3-dihydro-2-oxo-4-[(3-bromophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl)]- (9CI)

L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:991516 CAPLUS

DOCUMENT NUMBER: 140:42208

TITLE: Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists
 INVENTOR(S): Chaturvedula, Prasad V.; Chen, Ling; Ciavelli, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Karageorge, George W.; Luo, Guanglin; Macor, John E.; Poindexter, Graham Vig, Shikha

PATENT ASSIGNER(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 309 pp.

CODEN: PIXKX2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104236	A1	20031218	WO 2003-US16576	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487976	AA	20031218	CA 2003-2487976	20030527
AU 2003237255	A1	20031222	AU 2003-237255	20030527
BR 2003011812	A	20050329	BR 2003-11812	20030527
EP 1539766	A1	20050615	EP 2003-736721	20030527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671711	A	20050921	CN 2003-818475	20030527
JP 2005538959	T2	20051222	JP 2004-511306	20030527
NZ 537315	A	20060428	NZ 2003-537315	20030527
NO 2004005219	A	20050228	NO 2004-5219	20041129
PRIORITY APPLN. INFO.:				
US 2002-386138P P 20020605				
US 2002-388617P P 20020613				
US 2002-389870P P 20020619				
US 2002-393200P P 20020701				
US 2002-413534P P 20020925				
WO 2003-US16576 W 20030527				

OTHER SOURCE(S): MARPAT 140:42208
 GI

L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Diazabicyclics I [n, m = 0-2; m + n = 2; V = (un)substituted NH₂, OH, Q = (un)substituted alkyl, NH₂, NHCO₂H, NHCO₂Me; U = CH₂, NH; D = O, NCH₃, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic] were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepared from 1H-indazole-5-carboxaldehyde and had IC₅₀ for calcitonin gene related peptide receptor binding of ≤ 10 nM.


IT 635710-63-3P 635710-64-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RMT (Reactant or reagent); USES (Uses)
 (preparation of diazabicyclics as calcitonin gene related peptide receptor antagonists)

RN 635710-63-3 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-3-(1H-indazol-5-yl)-1-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 635710-64-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




IT 635710-13-3P 635710-16-6P 635710-44-0P
 635710-46-2P 635710-47-3P 635710-65-5P
 635710-66-6P 635710-67-7P 635710-68-8P
 635710-69-9P 635710-70-2P 635710-71-3P
 635710-72-4P 635710-73-5P 635710-74-6P
 635710-75-7P 635713-27-8P 635713-29-0P
 635713-36-9P 635713-37-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of diazabicyclics as calcitonin gene related peptide receptor antagonists)

RN 635710-13-3 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-(1H-indol-5-ylmethyl)-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-16-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-(1H-indol-5-ylmethyl)-2-[4-(2-methylpropyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-44-0 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-46-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-47-3 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(7-methyl-1H-indazol-5-yl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 635710-65-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-[4-(2-methylbutyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-66-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-(4-heptyl-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Habte

11/28/2006


L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME



RN 635710-67-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-(4-butyl-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 635710-68-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl)- (9CI) (CA INDEX NAME)




RN 635710-69-9 CAPLUS


L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-72-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-(4-(3-(dimethylamino)-2-propenyl)-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-73-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-(4-(2-ethyl-3-methylbutyl)-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-74-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-(4-(3-phenyl-2-propenyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-(4-(2-furanylmethyl)-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-70-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-(4-(2-ethylhexyl)-1-piperazinyl)-1-(1H-indazol-5-ylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635710-71-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-oxo-2-(4-(1H-pyrrol-2-ylmethyl)-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 635710-75-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-(1H-indazol-5-ylmethyl)-2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 635713-27-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[1-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 635713-29-0 CAPLUS

11/28/2006

L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1-Piperidinecarboxamide, N-[1-[(2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(ZH)-quinazoliny)- (9CI) (CA INDEX NAME)




RN 635713-36-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(2,3-dihydro-4-methyl-2-oxo-6-benzoxazolyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(ZH)-quinazoliny)- (9CI) (CA INDEX NAME)




RN 635713-37-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-chloro-2,3-dihydro-2-oxo-6-benzoxazolyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(ZH)-quinazoliny)- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 635710-04-2P 635710-06-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635710-04-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[2-[(4-(2-methylpropyl)-1-piperazinyl)-2-oxo-1-[[1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-5-yl]methyl]ethyl]- (9CI) (CA INDEX NAME)



RN 635710-06-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[2-[(4-(2-methylpropyl)-1-piperazinyl)-2-oxo-1-[[1-[[2-(trimethylsilyl)ethyl]sulfonyl]-1H-indol-5-yl]methyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2003:12037 CAPLUS
 DOCUMENT NUMBER: 138:297955
 TITLE: Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist
 AUTHOR(S): Hasbak, Philip; Opgaard, Ole Saetrum Eskesen, Karen; Schifter, Soren; Arendrup, Henrik; Longmore, Jenny; Edvinsson, Lars
 CORPORATE SOURCE: Department of Clinical Experimental Research, University Hospital of Copenhagen, Glostrup, Den.
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (2003), 304(1), 326-333
 CODEN: JPETAB; ISSN: 0022-3565
 PUBLISHED: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Calcitonin gene-related peptide (CGRP), adrenomedullin (AM), and amylin are structurally related peptides mediating vasorelaxation in the coronary circulation possibly via CGRP receptors (subtypes 1 or 2). Functional CGRP receptors appear to consist of at least three different kinds of proteins: the calcitonin receptor-like receptor (CRLR), receptor-activity-modifying proteins (RAMPs) and the receptor component protein (RCP). No CGRP2 receptor has yet been cloned. Using reverse transcriptase - polymerase chain reaction, the presence of mRNA sequences encoding CRLR, RCP and RAMPs was demonstrated in human coronary arteries. Relaxant responses were studied on isolated segments of coronary arteries after preconstriction with U46619 (9,11-dideoxy-11 α ,9 α -epoxymethano-prostaglandin F2 α). The human peptides α CGRP, AM, and amylin induced relaxation with mean pEC50 values of 8.6, 6.8, and 6.3 M, resp. Preincubation with α CGRP8-37 (10 $^{-7}$ -10 $^{-5}$ M) and a novel nonpeptide CGRP antagonist "Compound 1" (W098/11129) (10 $^{-7}$ -10 $^{-5}$ M) caused a dose-dependent rightward shift of the concentration-response curves for α CGRP with pA2 values of 7.0 and 7.1, resp. Preincubation with α CGRP8-37 (10 $^{-6}$ M) and Compound 1 (10 $^{-6}$ M) caused significant rightward shift of the concentration-response curves for AM and amylin as well with pKB values between 6.6 and 7.5. Preincubation with AM22-52 had no antagonistic effect on the AM and amylin response, neither did diacetamidomethyl cysteine CGRP cause any concentration dependent (10 $^{-11}$ -10 $^{-6}$ M) dilatation. In conclusion, mRNA for the components forming CGRP1 and AM receptors was detected in the human left anterior descending coronary arteries. α CGRP, AM, and amylin mediated vasorelaxation via the CGRP1 receptor. Compound 1 acted as a nonpeptide antagonist at the CGRP1 receptor and could thus become a tool for the study of CGRP-mediated functional responses in human tissue.

IT 344611-37-6, W098/11129
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
 (CGRP receptors and peptide pharmacol. in human coronary arteries in relation to characterization with nonpeptide antagonist)

RN 344611-37-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:539674 CAPLUS
 DOCUMENT NUMBER: 137:109273
 TITLE: Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
 INVENTOR(S): Urbanski, Maud J.; Gunnet, Joseph W., Jr.; Demarest, Keith T.
 PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 130 pp.
 CODEN: PIXXKD
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055514	A2	20020718	WO 2001-US51108	20011023
WO 2002055514	A3	20021121		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TG, TH, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, HT, IL, IN, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TG, TH, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW AU 2002243419 A1 20020724 AU 2002-243419 20011023 US 2003073842 A1 20030417 US 2001-47841 20011023 US 6653478 B2 20031125 EP 1330451 A2 20030730 EP 2001-989314 20011023 R: AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2004517872 T2 20040617 JP 2002-556183 20011023 PRIORITY APPLN. INFO.: US 2000-243917P P 20001027 WO 2001-US51108 W 20011023 OTHER SOURCE(S): MARPAT 137:109273 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [A = aryl or heteroaryl having 0-4 heteroatoms selected from N, O and S; X = S, O, NH, and NCH; Y = S or O; R1 = 1-3 groups selected from H, halo, NO2, (un)substituted alkyl, alkoxy, etc.; R2 = H, (un)substituted alkyl; R3 = H, benzhydryl, (un)substituted alkyl, aryl, heteroaryl, etc.; R4 and R5 independently = H, (un)substituted alkyl, etc., or nonexistent when n = 0; n = 0-1; m = 0-1, with proviso that when m = 0, X = O, and R3 = (un)substituted heteroaryl, CO2R6, and CONR6b wherein R6 and R6b independently = (un)substituted alkyl, aryl, heteroaryl, heterocyclyl, or R6aR6b as be taken together to form a group selected from (un)substituted heteroaryl or heterocyclyl, then n = 0] and their pharmaceutically acceptable salts are prepared and disclosed as vasopressin

L4 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 receptor antagonists or neuropeptide Y modulators. Thus, II was prepd. in 87% yield by addn. of benzhydryl isothiocyanate to 4-(2-keto-1-benzimidazolyl)piperidine. I were evaluated for their affinity with NPY-2 receptor, vasopressin-1a (V1a), -1b (V1b) and -2 (V2) receptors. For example, II was responsible for 52% inhibition of NPY-2 at 10 μ M, 38% inhibition of V2 at 1 μ M, 0% inhibition of V1b at concns. up to 10 μ M, and possessed an IC50 value of 0.59 μ M for V1a. As vasopressin antagonists and neuropeptide Y modulators, I are useful for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroke, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.

IT 442688-10-OP
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TBU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of piperidylbenzimidazolones as vasopressin receptor antagonists and neuropeptide y modulators)

RN 442688-10-0 CAPLUS
 CN Piperazine, 1-[(2S)-2-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]thioxomethyl]amino]-1-oxo-3-phenylpropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN


ACCESSION NUMBER: 2002:351484 CAPLUS
 DOCUMENT NUMBER: 137:304712
 TITLE: Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists
 AUTHOR(S): Malles, John J.; Salvatore, Christopher A.; Labourdelle, Beatrice; Oliver, Kevin R.; Longmore, Jenny; Koblan, Kenneth S.; Kane, Stefanie A.
 CORPORATE SOURCE: Molecular Pharmacology Department, Merck Research Laboratories, West Point, PA, 19486, USA
 SOURCE: Journal of Biological Chemistry (2002), 277(16), 14294-14298
 CODEN: JBCHA3; ISSN: 0021-9258
 PUBLISHER: American Society for Biochemistry and Molecular Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The heterodimeric CGRP receptor requires co-expression of calcitonin receptor-like receptor (CRLR) and an accessory protein called receptor activity-modifying protein (RAMP) 1. Several non-peptide CGRP receptor antagonists have been shown to exhibit marked species selectivity, with > 100-fold higher affinities for the human CGRP receptor than for receptors from other species. This observation provided an opportunity to map the determinants of receptor affinity exhibited by BIBN4096BS and its truncated analogs. All three compds. exhibited higher affinity for the human receptor, human CRLR/human RAMP1, than for the rat receptor, rat CRLR/rat RAMP1. We have now demonstrated that this species selectivity was directed exclusively by RAMP1. By generating recombinant human/rat CRLR/RAMP1 receptors, we demonstrated that co-expression of human CRLR with rat RAMP1 produced rat receptor pharmacol., and vice versa. Moreover, with rat/human RAMP1 chimeras and site-directed mutants, we have identified a single amino acid at position 74 of RAMP1 that modulates the affinity of small mol. antagonists for CRLR/RAMP1. Replacement of lysine 74 in rat RAMP1 with tryptophan (the homologous amino acid in the human receptor) resulted in a \geq 100-fold increase in antagonist affinities, similar to the Ki values for the human receptor. These observations suggest that important determinants of small mol. antagonist affinity for the CGRP receptor reside within the extracellular region of RAMP1 and provide evidence that this receptor accessory protein may participate in antagonist binding.

IT 204695-47-6 472966-25-9
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (receptor activity-modifying protein 1 detcs. the species selectivity of nonpeptide CGRP receptor antagonists)
 RN 204695-47-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




RN 472966-25-9 CAPLUS
 CN 1-Piperidinecarboxamide, 4-((2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-1-[(4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM

ACCESSION NUMBER: 2001:656252 CAPLUS

DOCUMENT NUMBER: 136:95802

TITLES:

CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with "Compound 1" (WO98/11128), a non-peptide antagonist

AUTHOR(S):

Hasbak, Philip; Sams, Anette; Schifter, Soren; Longmore, Jenny; Edvinsson, Lars

CORPORATE SOURCE:

Department of Clinical Experimental Research, Department of Clinical Physiology and Nuclear Medicine, University Hospital of Glostrup, Glostrup, Den.

SOURCE:

British Journal of Pharmacology (2001), 133(8), 1405-1413

CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 1 Calcitonin gene-related peptide (CGRP), amylin and adrenomedullin (AM) belong to the same family of peptides. Accumulating evidence indicate that the calcitonin (CT) receptor, the CT receptor-like receptor (CRLR) and receptor-activity-modifying proteins (RAMPs) form the basis of all the receptors in this family of peptides. 2 Using reverse transcriptase-polymerase chain reaction the presence of mRNA sequences encoding the CRLR, RAMP1 and RAMP2 were demonstrated in porcine left anterior descending (LAD) coronary arteries, whereas porcine calcitonin (CT) receptor mRNA was not present. The partial porcine mRNA sequences shared 92-92% nucleotide identity with human sequences. 3 The human peptides αCGRP, βCGRP, AM and amylin induced relaxation with pEC50 values of 8.1, 8.1, 6.7 and 6.1 M resp. 4 The antagonistic properties of a novel non-peptide CGRP antagonist "Compound 1" (WO98/11128), βCGRP8-37 and the proposed AM receptor antagonist AM22-52 were compared to the wellknown CGRP1 receptor antagonist αCGRP8-37. 5 The αCGRP8-37 and βCGRP8-37 induced concentration-dependent (10⁻⁷ - 10⁻⁵ M) rightward shift of both the αCGRP and βCGRP concentration-response curves. βCGRP8-37 (10⁻⁶ M) had the same effect as αCGRP8-37 (10⁻⁶ M), but with less potent rightward shift of the concentration-response curves for αCGRP, AM and amylin. 6 Preincubation with "Compound 1" (10⁻⁷ - 10⁻⁵ M) and AM22-52 (10⁻⁶ M) had no significant antagonistic effect. 7 In conclusion, the building blocks forming CGRP and AM receptors were present in the porcine LAD, whereas those of the amylin receptor were not. αCGRP, βCGRP, AM and amylin mediated vasorelaxation via the CGRP receptors. No functional response was detected to adrenomedullin via the adrenomedullin receptor.

IT

344611-37-6, WO 98/11128
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with "Compound 1" (WO98/11128), a non-peptide antagonist)

RN 344611-37-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM

ACCESSION NUMBER: 2001:164211 CAPLUS

DOCUMENT NUMBER: 135:40865

TITLES:

Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries

AUTHOR(S):

Edvinsson, L.; Sams, A.; Jansen-Olesen, I.; Tajti, J.; Kane, S. A.; Rutledge, R. T.; Kobian, K. S.; Hill, R. G.; Longmore, J.

CORPORATE SOURCE:

Department of Internal Medicine, Lund University Hospital, Lund, S-22185, Swed.

SOURCE:

European Journal of Pharmacology (2001), 415(1), 39-44

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The cerebral circulation is innervated by calcitonin gene-related peptide (CGRP) containing fibers originating in the trigeminal ganglion. During a migraine attack, there is a release of CGRP in conjunction with the head pain, and triptan administration abolishes both the CGRP release and the pain at the same time. In the search for a novel treatment of migraine, a non-peptide CGRP antagonist has long been sought. Here, we present data on a human cell line and human and guinea-pig isolated cranial arteries for such an antagonist, 4-((2-oxo-2,3-dihydro-benzimidazol-1-yl)piperidine-1-carboxylic acid [1-((3,5-dibromo-4-hydroxy-benzyl)-2-oxo-2-(4-phenyl-piperazin-1-yl)ethyl)amide] (I). On SK-N-MC cell membranes, radiolabeled CGRP binding was displaced by both CGRP-(8-37) and I, yielding pK_i values of 8.9 and 7.8, resp. Functional studies with SK-N-MC cells showed that CGRP-induced cAMP production was antagonized by both CGRP-(8-37) and I with pA₂ values of 7.8 and 7.7, resp. Isolated human and guinea pig cerebral arteries were studied with a sensitive myograph technique. CGRP induced a concentration-dependent relaxation in human


cerebral arteries which was antagonized by both CGRP-(8-37) and I in a competitive manner. In guinea pig basilar arteries, CGRP-(8-37) antagonized the CGRP-induced relaxation while I had a weak blocking effect. The clinical studies of non-peptide CGRP antagonists are awaited with great interest.

IT

344611-37-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (effects of CGRP receptor antagonist in human cerebral arteries)

RN 344611-37-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCESSION NUMBER: 2001:114968 CAPLUS
 DOCUMENT NUMBER: 134:183478
 TITLE: Use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes
 INVENTOR(S): Doods, Henri; Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard
 PATENT ASSIGNER(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010425	A2	20010215	WO 2000-EP7613	20000805
WO 2001010425	A3	20020207		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GN, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19937304	A1	20010315	DE 1999-19937304	19990810
DE 19937304	C2	20030821		
US 6521609	B1	20030218	US 2000-614343	20000712
CA 2378428	AA	20010215	CA 2000-2378428	20000805
BR 2000013009	A	20020430	BR 2000-13009	20000805
TR 200200359	T2	20020521	TR 2002-359	20000805
EP 1207884	A2	20020529	EP 2000-958385	20000805
EP 1207884	B1	20041103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ZA 2002000997	A	20020821	ZA 2002-997	20000805
HU 200202397	A2	20021028	HU 2002-2397	20000805
JP 2003056403	T2	20030218	JP 2001-514945	20000805
EE 200200061	A	20030415	EE 2002-61	20000805
NZ 517367	A	20040924	NZ 2000-517367	20000805
AU 777709	B2	20041028	AU 2000-69928	20000805
AT 281168	E	20041115	AT 2000-958385	20000805
PT 1207884	T	20041231	PT 2000-958385	20000805
ES 2231243	T3	20050516	ES 2000-958385	20000805
BG 106391	A	20020930	BG 2002-106391	20020206
NO 2002000605	A	20020207	NO 2002-605	20020207
HK 1046854	A1	20050225	HK 2002-108347	20021119

PRIORITY APPL. INFO.:
 DE 1999-19937304 A 19990810
 US 2000-184800P P 20000224
 WO 2000-EP7613 W 20000805

AB The invention relates to the use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes. Thus, tablets contained a piperazine derivative containing D-tyrosine and D-lysine residues 20,

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 lactose 120, corn starch 40, Mg stearate 2, and Povidone K-25 18 mg.
 IT 204696-63-9 205061-76-3 205063-65-6
 205063-67-8 205063-68-9 205063-69-0
 205063-87-2 205063-89-4 205064-45-5
 205064-53-5 205064-61-5 205065-28-7
 205065-32-3 205066-02-0 205260-29-3 20526
 0-31-7 205260-32-8 325975-87-9
 RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes)
 RM 204696-63-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RM 205061-76-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RM 205063-65-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RM 205063-67-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-(3-thienyl)-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205063-68-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-69-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-45-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-53-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-87-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205063-89-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-61-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205065-28-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-{(1-methyl-4-piperidinyl)-1-piperazinyl}-2-oxoethyl)-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205065-32-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205260-31-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.



RN 205260-32-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.

Habte


L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

-NMe2

RN 205066-02-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-9CI (CA INDEX NAME)


Absolute stereochemistry.



RN 205260-29-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-9CI (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 325975-87-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.




IT 205260-30-6
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ed)CGRP antagonists and CGRP release inhibitors for controlling
 menopausal hot flashes)

RN 205260-30-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.

11/28/2006

L4 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:643016 CAPLUS

DOCUMENT NUMBER: 133:223016

TITLE: Preparation of amino acid amide derivatives for use as calcitonin gene-related peptide antagonists in pharmaceutical compositions

INVENTOR(S): Eberlein, Wolfgang; Rudolf, Klaus; Engel, Wolfhard;

Doods, Henric; Hallermayer, Gerhard

PATENT ASSIGNER(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: Ger. Offen., 36 pp.

CODEN: GWAXEX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19911039	A1	20000914	DE 1999-19911039	19990312
CA 2361939	AA	20000921	CA 2000-2361939	20000308
WO 2000055154	A1	20000921	WO 2000-EP2004	20000308
V: AR, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, C2, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GE, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1163239	A1	20011219	EP 2000-922505	20000308
EP 1163239	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002539208	T2	20021119	JP 2000-605583	20000308
JP 3719937	B2	20051124		
AT 241616	E	20030615		
PT 1163239	T	20031031	AT 2000-922505	20000308
ES 2199819	T3	20040301	PT 2000-922505	20000308
US 6313097	B1	20011106	ES 2000-922505	20000308
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): MARPAT 133:223053				
GI				
WO 2000-EP2004				
W 20000308				

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds., e.g. (I) see patent for general claims), were prepared and tested as CGRP antagonists for use in pharmaceutical preps. for treatment of headache, non-insulin dependent diabetes mellitus, cardiovascular diseases, skin diseases, inflammatory diseases, allergic rhinitis, asthma, morphine tolerance, and menopausal hot flashes (formulations given), and for use as diagnostic or anal. aides in RIA or ELISA assays and as diagnostic or analytic auxiliary agents in neurotransmitter research. Thus, di-Ph methanesulfonylimidocarbonate was reacted with 1-(4-amino-3,5-dibromo-0-phenylalanyl)-4-(1-piperidinyl)piperidine (as the bis-trifluoroacetate salt), and the product further reacted with 3,4-dihydro-3-(4-piperidinyl)-2(H)-quinazolinone to give 1 (278). In in vitro tests of human calcitonin gene related peptide (CGRP) receptor binding using 5k-M-MC-cells, title compds. had IC₅₀ ≤ 104 nM, and in the same system, had CGRP-antagonist activity at doses from 10-11-10-5M.

IT 291509-50-7P 291509-52-9P 291509-68-7P

291509-69-8P 291509-71-2P 291509-72-3P

291509-77-8P 291509-86-9P 291509-87-0P

291509-91-0P 291509-93-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino acid amide derivs. for use as calcitonin gene-related peptide antagonists)

PN 291509-50-7 CAPLUS

CN Piperazine, 1-[(2R)-2-[(cyanoamino)[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]methylene]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 291509-52-9 CAPLUS

CN Piperazine, 1-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[(cyanoamino)[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]methylene]amino]-1-oxopropyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 291509-68-7 CAPLUS

CN Piperazine, 1-[(2R)-2-[(cyanoamino)[4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl]methylene]amino]-3-(3,5-dibromo-4-

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
hydroxyphenyl)-1-oxopropyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 291509-69-8 CAPLUS
CN Piperazine, 1-[(2R)-2-[[[(cyanoamino)[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]methylene]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 291509-71-2 CAPLUS
CN Piperazine, 1-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[[(cyanoamino)[4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-1-piperidinyl]methylene]amino]-1-oxopropyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 291509-72-3 CAPLUS
CN Piperazine, 1-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[[(cyanoamino)[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]methylene]amino]-1-oxopropyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 291509-77-8 CAPLUS
CN Piperazine, 1-[2-[[[(cyanoamino)[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]methylene]amino]-3-(3,5-dibromo-4-methylphenyl)-1-oxopropyl]-4-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 291509-86-9 CAPLUS
CN Piperazine, 1-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[[(cyanoamino)[4-(7-methoxy-1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-


Habte

11/28/2006

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 piperidinyl)methylene]amino]-1-oxopropyl]-4-(1-methyl-4-piperidinyl)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Br


PAGE 2-A

RN 291509-87-0 CAPLUS
 CN Piperazine, 1-[(2R)-3-(4-amino-3,5-dibromophenyl)-2-[[[(cyanoamino)[4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)-1-piperidinyl)methylene]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropyl]-4-(1-methyl-4-piperidinyl)-piperazine-1-yl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



Br


PAGE 2-A

RN 291509-91-6 CAPLUS
 CN Piperazine, 1-[(2R)-2-[[[(cyanoamino)[4-(7-methoxy-1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl)methylene]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropyl]-4-(1-methyl-4-piperidinyl)-piperazine-1-yl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



Br


PAGE 2-A

RN 291509-93-8 CAPLUS
 CN Piperazine, 1-[(2R)-2-[[[(cyanoamino)[4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)-1-piperidinyl)methylene]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropyl]-4-(1-methyl-4-piperidinyl)-piperazine-1-yl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




Br

PAGE 2-A

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 128:257695
 DOCUMENT NUMBER: 1998:197358 CAPLUS
 TITLE: Preparation of modified amino acids and their use as calcitonin gene-related peptide antagonists in pharmaceutical compositions
 INVENTOR(S): Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Pieper, Helmut; Doods, Henri; Hallermeier, Gerhard; Entzerth, Michael; Wienen, Wolfgang
 PATENT ASSIGNEE(S): Karl Thomas G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 461 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9811128	A1	19980319	WO 1997-EP4862	19970908
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BT, CA, CH, CN, CU, DE, DK, EE, ES, FI, GB, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, NG, SN, TD, TG				
DE 19636623	A1	19980312	DE 1996-19636623	19960910
DE 19720011	A1	19981119	DE 1997-19720011	19970514
CA 2262818	AA	19980319	CA 1997-2262818	19970908
AU 9741196	A1	19980402	AU 1997-41196	19970908
AU 721035	B2	20000622		
EP 927192	A1	19990707	EP 1997-938928	19970908
EP 927192	B1	20040512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9712023	A	19990831	BR 1997-12023	19970908
JP 2000505100	T2	20000425	JP 1998-513227	19970908
JP 3483893	B2	20040106		
AT 266673	E	20040515	AT 1997-938928	19970908
EE 4375	B1	20041015	EE 1999-115	19970908
PL 190180	B1	20051130	PL 1997-331989	19970908
NO 9901130	A	19990505	NO 1999-1130	19990309
KR 200004040	A	20000715	KR 1999-702008	19990310
BG 64214	B1	20040531	BG 1999-103250	19990315
US 6344449	B1	20020205	US 1999-254281	19991012
HK 1021192	A1	20040430	HK 1999-105722	19991208
US 2001036946	A1	20011001	US 2001-789391	20010221
US 2003069231	A1	20030410	US 2002-119875	20020410
US 2004214819	A1	20041028	US 2004-835495	20040429
PRIORITY APPL. INFO.:				
			DE 1996-19636623	A 19960910
			DE 1997-19720011	A 19970514
			WO 1997-EP4862	V 19970908
			US 1999-254281	A1 19991012
			US 2001-789391	A1 20010221

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 OTHER SOURCE(S): MARPAT 128:257695 US 2002-119875 B1 20020410
 GI



AB The invention concerns modified amino acids of general formula I (A = bond, CH₂ = CH₂, NR₁; R₁ = H, alkyl, phenyl-alkyl; X = O, H, H; n = 1-2; m = 0-1; R = (substituted)alkyl; R₂ = Ph, (substituted) (hetero) (bi)cyclo; R₃ = H, (substituted)alkyl, Ph, pyridinyl; R₄ = H, (substituted)alkyl; R₃R₄ = (hetero) cyclo; R₅ = H, alkyl, alkoxy-carbonyl, PhCH₂), pharmaceuticals containing these compounds, their use and the method for their production, as well as their use for the production and purification of antibodies and as marked compounds in RIA and ELISA assays and as diagnostic or analytic auxiliary agents in neurotransmitter research. Thus, 3,5-dibromo-N₂-(4-(1,3-dihydro-2(1H)-oxo-benzimidazol-1-yl)-1-piperidinyl)carbonyl-D-tyrosine was reacted with 1-(4-pyridinyl)-piperazine, to give II (22a). Title compounds show human calcitonin gene related peptide (CGRP) antagonist activity; in in-vitro binding studies with Sk-N-MC-cells, I had IC₅₀ <10000 nM, and in the same system, had CGRP-antagonist activity at doses from 10-11 to 10-6 M.


IT 204695-32-9P 204695-34-1P 204695-39-6P
 204695-40-9P 204695-45-4P 204695-46-5P
 204695-47-6P 204695-49-8P 204695-51-2P
 204695-93-2P 204695-94-3P 204695-96-5P
 204695-98-7P 204696-00-4P 204696-01-5P
 204696-02-6P 204696-03-7P 204696-06-0P
 204696-07-1P 204696-08-2P 204696-17-3P
 204696-19-5P 204696-20-8P 204696-25-3P
 204696-26-4P 204696-30-0P 204696-31-1P
 204696-33-3P 204696-34-4P 204696-46-8P
 204696-53-7P 204696-61-7P 204696-63-9P
 204696-65-1P 204696-73-1P 204696-74-2P
 204696-75-3P 204696-78-6P 204696-79-7P

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)

204696-92-4P 204696-96-8P 204697-01-8P
 204697-36-9P 204697-40-5P 204697-41-6P
 204697-42-7P 204697-43-8P 204697-44-9P
 204697-45-0P 205061-62-7P 205061-68-3P
 205061-69-4P 205061-76-3P 205061-77-4P
 205061-78-5P 205061-79-6P 205061-80-9P
 205061-82-1P 205061-84-3P 205061-88-7P
 205061-89-8P 205061-90-1P 205061-96-7P
 205061-97-8P 205061-99-0P 205062-06-2P
 205062-14-2P 205062-16-4P 205062-18-6P
 205062-20-0P 205062-80-2P 205062-81-3P
 205062-83-5P 205062-88-0P 205062-90-4P
 205062-91-5P 205063-22-5P 205063-30-5P
 205063-34-9P 205063-65-6P 205063-67-8P
 205063-68-9P 205063-69-0P 205063-72-5P
 205063-87-2P 205063-89-4P 205064-04-6P
 205064-09-1P 205064-11-5P 205064-12-6P
 205064-13-7P 205064-14-8P 205064-15-9P
 205064-16-0P 205064-17-1P 205064-18-2P
 205064-20-6P 205064-23-9P 205064-25-1P
 205064-30-8P 205064-31-9P 205064-33-1P
 205064-35-3P 205064-39-7P 205064-40-0P
 205064-41-1P 205064-43-3P 205064-44-4P
 205064-45-5P 205064-47-7P 205064-52-4P
 205064-53-5P 205064-54-6P 205064-57-9P
 205064-61-5P 205064-95-5P 205065-11-8P
 205065-26-5P 205065-27-6P 205065-28-7P
 205065-29-8P 205065-30-1P 205065-32-3P
 205065-33-4P 205065-34-5P 205065-35-6P
 205065-67-4P 205065-93-6P 205065-94-7P
 205066-02-0P 205066-68-8P 205066-80-4P
 205260-29-3P 205260-30-6P 205260-31-7P
 205260-32-8P
 RL: BAC (Biological activity or effector, except adverse); RSU (Biological study, unclassified); SPW (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of amino acids and their use as calcitonin gene-related peptide antagonists in pharmaceutical compns.)
 RN 204695-32-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204695-34-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3-bromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-39-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-40-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-45-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-49-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-51-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3-bromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-46-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(1-methyl-4-piperidinyl)-1-piperazinyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-47-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-93-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-94-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-96-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-98-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-pyrazinyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-02-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-03-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(5-methoxy-4-pyridinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-00-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-01-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-06-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-07-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204696-08-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-17-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204696-25-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-26-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204696-19-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-20-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204696-30-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-31-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-33-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-34-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-61-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-63-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-46-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-53-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-65-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-73-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(5,6-dichloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 204696-74-2 CAPLUS
 CN 1H-Benzimidazole-1-acetic acid, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo-methyl ester, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204696-75-3 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-[(4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-, (R)-(9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-92-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204696-96-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 204696-78-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(4-fluorophenyl)-1-piperazinyl)-2-oxoethyl]-4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 204696-79-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-(2-fluorophenyl)-1-piperazinyl)-2-oxoethyl]-4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 204697-01-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(2,5-dibromophenyl)methyl]-2-oxo-2-[(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (9CI) (CA INDEX NAME)



RN 204697-36-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[(4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl)-2-oxoethyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204697-40-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(3,4-dihydro-1,1-dioxo-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204697-41-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(5-methoxy-4-pyridinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-5-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204697-44-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204697-45-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-5-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204697-42-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204697-43-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205061-62-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-[4-(1-cyclohexyl-4-piperidinyl)-1-piperazinyl]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205061-68-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205061-69-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[(3-exo)-6-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205061-76-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-N-[2-[(3-exo)-6-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205061-79-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-N-[2-[(3-exo)-6-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205061-80-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-N-[2-[(3-exo)-6-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205061-77-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-N-[2-[(3-exo)-6-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205061-78-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-N-[2-[(3-exo)-6-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205061-82-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-N-[2-[(3-exo)-6-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 205061-84-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-3(2H)-quinazolinyl]-N-[2-[(3-exo)-6-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205061-88-7 CAPLUS
 CN Piperazine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-(9CI) (CA INDEX NAME)




RN 205061-89-8 CAPLUS
 CN Piperazine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205061-96-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-[(4-cycloheptyl-1-piperazinyl)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205061-97-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[2-[(4-cyclopentyl-1-piperazinyl)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habte

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 205061-90-1 CAPLUS
 CN Piperazine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-(9CI) (CA INDEX NAME)


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205061-99-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[[[3,5-bis(trifluoromethyl)phenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 205062-06-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[[[3,5-bis(trifluoromethyl)phenyl)methyl]-2-oxo-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




11/28/2006

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 205062-14-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-[(3-methoxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 205062-16-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-[(3-methoxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 205062-18-6 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[1-[(3-methoxyphenyl)methyl]-2-[4-(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205062-81-3 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)




RN 205062-83-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)




RN 205062-88-0 CAPLUS
 CN Piperazine, 1-[4-[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]-4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)

Have

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205062-20-0 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[2-[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-1-[[3-(methoxyphenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 205062-80-2 CAPLUS
 CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-N-[2-[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Relative stereochemistry.




RN 205062-90-4 CAPLUS
 CN Piperazine, 1-[4-[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 205062-91-5 CAPLUS
 CN Piperazine, 1-[4-[4-(1,4-dihydro-2-oxo-3(ZH)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)


11/28/2006

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-22-5 CAPLUS

CN Piperazine, 1-[2-[(3,5-dibromo-4-methylphenyl)methyl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-[(4-(dimethylamino)butyl)phenyl]- (9CI) (CA INDEX NAME)




RN 205063-30-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-[(2,3-dihydro-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-67-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-[(2,3-dihydro-2-oxo-4-(3-thienyl)-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-68-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-[(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Habte


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-34-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-[(2,3-dihydro-4-(4-methoxyphenyl)-2-oxo-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-65-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-[(2,3-dihydro-2-oxo-4-(3-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-69-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-[(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205063-72-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl]-4-[(1,4-dihydro-2-oxothieno[3,2-d]pyrimidin-3(2H)-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205063-87-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205063-89-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-11-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-12-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-04-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-09-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-13-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-14-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-15-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-16-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-20-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205064-23-9 CAPLUS
 CN [1,4'-Bipiperidine]-1'-carboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Hatte

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-17-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-18-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-25-1 CAPLUS
 CN [1,4'-Bipiperidine]-1'-carboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205064-30-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


11/28/2006

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-31-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyrimidinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-33-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyrimidinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-40-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-41-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-ethylphenyl)-1-piperazinyl)ethyl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-35-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl)ethyl]-4-(4-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-39-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-1-piperazinyl)ethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-43-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-44-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-45-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-2-[4-(4-acetylphenyl)-1-piperazinyl]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-47-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-54-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-57-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205064-52-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1-methyl-4-piperidinyl)carbonyl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205064-53-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205064-61-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205064-95-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205065-11-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205065-26-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-(4'-acetyl[1,1'-bipiperazin]-4-yl)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205065-29-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205065-30-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205065-27-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-(4'-acetyl[1,1'-bipiperazin]-4-yl)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205065-28-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205065-32-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

PAGE 1-B

—NMe2

RN 205065-33-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(4-(dimethylamino)butyl)phenyl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205065-34-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 205065-93-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205065-94-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 205065-35-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205065-67-4 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 205066-02-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(5-methoxy-4-pyridinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 205066-68-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205066-80-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-([1-[(3-chlorophenyl)methyl]-2-(4-cyclopentyl-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)




RN 205260-29-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-([1R]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 205260-32-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-([1R]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-4-(3-methoxyphenyl)-2-oxo-1H-imidazol-1-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


Habte

L4 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205260-30-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-([1R]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205260-31-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-([1R]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[4-(3-bromophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-(9CI)

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN

1998:186625 CAPLUS

128:230701

Preparation of varied amino acids as calcitonin gene-related peptide antagonists in pharmaceutical compositions

INVENTOR(S): Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Pieper, Helmut; Doods, Hans; Hallermeier, Gerhard; Entzeroth, Michael; Wienen, Wolfgang

PATENT ASSIGNEE(S): Karl Thomae G.m.b.H., Germany

SOURCE: Ger. Offen., 142 pp.

CODEN: GWXKX

Patent

German


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19636623	A1	19980312	DE 1996-19636623	19960910
CA 2262818	AA	19980319	CA 1997-2262818	19970908
WO 9811128	A1	19980319	WO 1997-EP4862	19970908
V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, SJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9741196	A1	19980402	AU 1997-41196	19970908
AU 721035	B2	20000622		
EP 927192	A1	19990707	EP 1997-938928	19970908
EP 927192	B1	20040512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9712023	A	19990831	BR 1997-12023	19970908
CN 1230196	A	19990929	CN 1997-197772	19970908
CN 1129605	B	20031203		
JP 2000505100	T2	20000425	JP 1998-513227	19970908
JP 3483893	B2	20040106		
JP 2003300959	A2	20031021	JP 2003-21750	19970908
AT 266673	E	20040515	AT 1997-938928	19970908
EP 1440976	A1	20040728	EP 2004-3959	19970908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PT 927192	T	20040930	PT 1997-938928	19970908
EE 4375	B1	20041015	EE 1999-115	19970908
ES 2221691	T3	20050101	ES 1997-938928	19970908
PL 190180	B1	20051130	PL 1997-331989	19970908
ZA 9708083	A	19991217	ZA 1997-8083	19970909
HR 970481	B1	20031031	HR 1997-481	19970909
TW 477792	B	20020301	TW 1997-86113120	19970910
TW 498076	B	20020811	TW 2000-89125839	19970910
NO 9901130	A	19990505	NO 1999-1130	19990309
BG 64214	B1	20040531	BG 1999-103250	19990315
US 6344449	B1	20020205	US 1999-254281	19991012
HK 1021192	A1	20040430	HK 1999-105722	19991208
PRIORITY APPL. INFO.:				
			DE 1996-19636623	A 19960910
			DE 1997-19720611	A 19970514

11/28/2006

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 EP 1997-938928 A3 19970908
 JP 1998-513227 A3 19970908
 WO 1997-EP4862 W 19970908
 OTHER SOURCE(S): MARPAT 128:230701
 GI




II

AB Title compds. R002CRL12C(X)NR3R4 [(I); R = (substituted) alkyl; R1 = H, alkyl, PhCH2; R2 = (CO)m(CH2)nR5; m = 0, 1; n = 1, 2; R5 = Ph, heterocycle; X = O, (H,H); Z = CH2; NR6; R6 = H, alkyl, phenyl-alkyl; A = bond, proline; R3 = H, substituted alkyl, Ph, pyridinyl; R4 = H, substituted alkyl; NR3R4 = (substituted) heterocycle], useful as calcitonin gene-related peptide (CGRP) antagonists, were prepared. Thus, 3,5-dibromo-N2-(4-(1,3-dihydro-2(2H)-oxo-benzimidazol-1-yl)-1-piperidinyl)carbonyl-D-tyrosine was reacted with 1-(4-pyridinyl)-piperazine, to give II (22a). In in-vitro binding studies with human CGRP-receptors, I had IC50 <10000 nM; in CGRP-antagonist in vitro tests, I was effective at doses from 10-11 to 10-5 M.


IT 204695-32-9P 204695-34-1P 204695-39-6P
 204695-40-9P 204695-45-4P 204695-46-5P
 204695-47-6P 204695-49-8P 204695-51-2P
 204695-93-2P 204695-94-3P 204695-96-5P
 204695-98-7P 204696-00-4P 204696-01-5P
 204696-02-6P 204696-03-7P 204696-06-0P
 204696-07-1P 204696-08-2P 204696-17-3P
 204696-19-5P 204696-20-8P 204696-25-3P
 204696-26-4P 204696-30-0P 204696-31-1P
 204696-33-3P 204696-34-4P 204696-35-5P
 204696-46-8P 204696-53-7P 204696-61-7P
 204696-63-9P 204696-65-1P 204696-73-1P
 204696-74-2P 204696-75-3P 204696-78-6P
 204696-79-7P 204696-92-4P 204696-96-8P
 204697-01-8P 204697-36-9P 204697-40-5P
 204697-41-6P 204697-42-7P 204697-43-8P

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-39-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 204695-40-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 204697-44-9P 204697-45-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of amino acids and their use as calcitonin gene-related peptide antagonists in pharmaceutical compns.)
 RN 204695-32-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-34-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3-bromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-45-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-46-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-(4-methyl-1-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-47-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-49-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-94-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-96-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-51-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3-bromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204695-93-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204695-98-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-00-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(2-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204696-01-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-02-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204696-07-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(5-methoxy-4-pyridinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-08-2 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(5-methoxy-4-pyridinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204696-03-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-pyrazinyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-06-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



RN 204696-17-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(octahydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-19-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-20-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-25-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-31-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-33-3 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-26-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-30-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-34-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-35-5 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-46-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-], (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-53-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-], (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-65-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-], (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-73-1 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(5,6-dichloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-], (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-61-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-63-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-74-2 CAPLUS
 CN 1H-Benzimidazole-1-acetic acid, 3-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo-, methyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-75-3 CAPLUS
 CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1-[(4-hydroxyphenyl)methyl]-2-oxo-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl)-], (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-78-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 204696-79-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 204697-01-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(2,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)



RN 204697-36-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204696-92-4 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204696-96-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204697-40-5 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 204697-41-6 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-5-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204697-42-7 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-(4-fluorophenyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 204697-43-8 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[(4-(4-fluorophenyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 204697-44-9 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-(2-fluorophenyl)-1-piperazinyl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204697-45-0 CAPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[(4-(2-fluorophenyl)-1-piperazinyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-5-phenyl-1H-imidazol-1-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.